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The first part of this thesis focuses on perinatal morbidity, induction of labor and trends in CS 
during the past decade in the Netherlands. Analyses are performed on a macro-level, to look 
at the effects of changing obstetric practice in the Netherlands. 
 
Perinatal outcome 
Perinatal mortality is an important parameter when analysing obstetric care. The Peristat 
project, a European collaborative study in which indicators for perinatal health have been 
defined, has resulted in an increased awareness to perinatal mortality figures in the 
Netherlands1-4.  The Netherlands have higher perinatal mortality rates compared to other 
European countries, especially when compared to countries with a similar socio-economic 
position. Many reports have since then been published about this subject, focusing on  
possible mechanisms to explain those relatively high figures. The discussion has put forward 
that obstetric care should be critically evaluated1-4. 
During the past decade the perinatal mortality rate in the Netherlands has dropped, from 
11.4 per 1000 in Peristat I (1999)5, to 7.0 per 1000 in Peristat II (2004), to 5.1 per 1000 in 
Peristat III (2011)6. The ranking compared to other European countries has also improved, 
although the position of the Netherlands still remains unfavourable6.  
The main causes of perinatal mortality in the Netherlands are one or more of the so-called 
“big-four” causes; congenital malformations, preterm labor, intra-uterine growth restriction 
and APGAR-score below seven after five minutes2. These four causes of perinatal mortality, 
together account for about 85% of all perinatal deaths in the Netherlands2. To prevent those 
big-four problems multiple initiatives have been implemented. The main changes in 
management have been: the introduction of perinatal audits7, team training for obstetric 
emergencies8,9 and a structural ultrasound scan at 20 weeks gestation for all pregnant 
women since 20072. 
The management of suspected intra-uterine growth restriction (IUGR) - which is an 
estimated fetal weight (EFW) of <10th percentile (p10) or an abdominal circumference (AC) 
<p10 or flattening of the fetal growth curve - has changed tremendously in recent years. The 
outcome of a large randomized multi-centre trial in the Netherlands in 2010 (DIGITAT) has 
shown that, when comparing induction of labor to expectant management in suspected fetal 
IUGR, no benefit was found regarding neonatal outcomes or operative delivery rates when 
practicing expectant management10. In this study induction of labor is therefore considered 
a ‘rational option’ to prevent stillbirth and neonatal morbidity10. 
 
Induction of labor 
Not only the DIGITAT study has possibly resulted in higher induction rates. Worldwide an 
increasing trend in induction rates is seen11. Many other large clinical trials have been 
performed, for example in hypertension and pre-eclampsia at term,  showing a more 
beneficial maternal outcome in the induced group compared to expectant management12. 
The need for induction in pregnancies at or beyond term, remains a topic of debate. A higher 
incidence of meconium stained amniotic fluid (MSAF) is seen with advancing gestational 
age13. Although the pathophysiologic phenomenon of the presence of MSAF remains 
indistinct, its presence puts neonates at risk for the meconium aspiration syndrome14. The 
meconium aspiration syndrome still has a high perinatal mortality rate today and is thus of 
clinical importance14. A Cochrane review of 2012 has shown that induction of labor leads to 
less overall perinatal mortality and a decrease in CS, although the number needed to treat is 
high15.  Furthermore, significantly less infants had the meconium aspiration syndrome in the 
induced group. The suggestion of the authors is, to offer women the option of induction for 
postdate pregnancies after extensive counseling15. Furthermore, many elective inductions 
are performed, as the increase of inductions is higher than the increase of medical 
complications, for which a medical indicated induction should be performed11. 
The relation between induction rates and increased risk of CS remains controversial16-20. 
Many reports have shown an association between induction and CS in general, compared to 
women in spontaneous labor16,17. However, Caughey et al. have introduced the concept that 
induction of labor should not be compared to spontaneous labor, but to expectant 
management instead18. In every day practice, expectant management can still result in 
induction of labor at a later time due to changing circumstances. Therefore, a comparison 
between expectant management and induction of labor has to be performed for every 
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gestational week. When induction of labor is compared to expectant management for each 
gestational week, no increased odds for CS are found when labor is induced18-20.  
 
Caesarean sections 
CS rates are increasing globally, but there are concerns that this worldwide trend does not 
lead to improved perinatal outcomes21,22, but instead leads to increased maternal morbidity 
in the index and possible subsequent pregnancies23-25. Risks of (multiple) CS are uterine 
rupture, placenta accreta and emergency peripartum hysterectomy23-25. The World Health 
Organization has stated that CS-rates >15% cannot be justified in any centre26, but currently  
this rate is much higher in most developed countries. An international study from Ye et al. 
has confirmed that a CS rate above 10% does not improve maternal or neonatal outcome 
any further and is thus not desirable27.  
Reasons for increased CS rates could possibly be induction of labor as discussed above, but 
also a trend is seen towards more complicated pregnancies, with a higher risk of CS, due to 
for example obesity and increasing maternal age in nulliparous women28,29. Furthermore, 
there is unwillingness of both patients and doctors to take a risk for intrapartum asphyxia. 
One of the historic determinants of fetal distress, meconium-stained amniotic fluid, is still 
associated with higher CS-rates today30. CS on maternal request is another topic of debate 
and currently occurs in about 3% of all deliveries in the US31. There are some studies that 
report less neonatal morbidity and mortality when an elective CS is performed at term 
compared to expectant management32, but most studies do not report any reduction in 
health risks of mothers or children31. 
SECTION II 
 
The second part of this thesis will assess perinatal and maternal outcome at a “micro-level”. 
The thyroid gland is found to be an important factor in many major obstetric outcome 
measures. That is why the second part of this thesis focuses on maternal thyroid 
(dys)function during pregnancy and its effects on the mode of delivery and perinatal 
outcomes.  
 
Thyroid function in pregnancy 
The thyroid gland produces the hormones thyroxine (T4) and triiodothyronine (T3) which are 
important for human metabolism. During pregnancy the thyroid gland enlarges and 
becomes hypervascularized. The thyroid hormones are stimulated by thyrotrophine-
stimulating hormone (TSH) which has structural homology to beta-humane chorionic 
gonadotropin (β-hCG). β-hCG is highest in the first trimester of pregnancy. As β-hCG mimics 
the function of TSH, the levels of T4 will physiologically be 30-100% higher in the first 
trimester of pregnancy compared to pre-pregnancy values32-34. The availability of T4 and T3 
is further enhanced by the increased availability of thyroxine binding globuline (TBG), which 
carries the thyroid hormones into the bloodstream35. The TBG production in the liver is 
increased during pregnancy and degradation is prolonged due to higher estrogen-
levels33,35,37. TBG shows a plateau around 24 weeks, whilst the plateau for T4 is around 20 
weeks35. TSH is suppressed in the first trimester of pregnancy and then increases during the 
course of pregnancy and is highest during the last trimester34,36. Due to these physiologic 
changes, trimester-specific reference ranges should be used when assessing thyroid function 
(preferentially of TPO-Ab negative women with sufficient iodine intake)33,35,37-39. 
 
Measurement methods 
Although there is consensus about the need for trimester-specific reference ranges for 
thyroid dysfunction, there is still controversy about the proper cut off values and the 
methodology that should be used for thyroid function tests. It is advised that trimester-
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specific reference ranges are determined for each laboratory individually, preferentially in 
TPO-Ab negative women, as both the methodology used and the iodine status of individuals 
determines the reference ranges39-43. When population-based trimester-specific reference 
ranges are not available the current guidelines recommend a cut-off value for TSH of 2.5 
mU/L in the first trimester and 3.0 mU/L in the second and third trimester of pregnancy42-44. 
Ethnicity also plays an important role when assessing thyroid function; in the Generation R 
study 18% of the diagnoses of thyroid dysfunction had to be revised when using ethnicity 
specific reference ranges, compared to reference ranges for the total population44.  
There are different assays to test TSH and fT4. Especially the measurement of fT4 is 
challenging, as small amounts of free hormone should be detected, compared to high 
amounts of protein-bound analyte45. In pregnancy there is an increased chance of error 
when using immunoassays46. When analyzing the literature for thyroid function in pregnancy 
the variety in tests used is enormous for fT4 measurements.  
Overt hypothyroidism (OH) in pregnancy is defined as both a high TSH and a low fT4, for the 
reference ranges of pregnancy. Subclinical hypothyroidism (SCH) is defined as a higher TSH 
than the pregnancy reference ranges, but a normal fT4. The prevalence of OH is 0.2-0.5% , 
compared to 2-2.5% for SCH41. Isolated hypothyroxinemia is also described in pregnancy47 
and refers to fT4 in the lower reference range with normal TSH and is preferentially seen in 
iodine deficient areas. Hyperthyroidism is defined as a low TSH and high fT4. Because most 
research focus on the possible detrimental effect of (sub)clinical hypothyroidism on obstetric 
outcome, hyperthyroidism is not further discussed in this thesis.  
Screening 
Apart from the difficulties measuring and interpreting thyroid function test in pregnancy, 
much discussion remains about which women to test and when to test them. The urgency 
for universal screening is currently being debated39,48-51. Universal screening has already 
been proven cost effective, even when compared to selective screening for high risk 
women52,53. It is known that up to 50% of cases of thyroid dysfunction are missed when 
targeted case-finding is performed, when compared to universal screening at the beginning 
of pregnancy48. Levothyroxine treatment  has shown no disadvantageous side effects on 
newborns. However, it has shown beneficial effects on many important obstetric outcomes, 
including childhood cognitive effects, although the benefit of treatment remains unclear for 
some outcomes in mild thyroid dysfunction39,49,54. In women undergoing assisted 
reproductive techniques the benefit of treatment before conception in order to prevent 
miscarriages has been demonstrated in some studies55. However, to date, despite beneficial 
effects of treatment with levothyroxine, universal screening is not currently recommended 
by the European Thyroid Association nor by the American Thyroid Association, as there is 
lack of grade 1 evidence39,43. However, the topic remains controversial, even within the team 
of the guideline development39.  
 
Maternal thyroid function and obstetric outcome 
Obstetric outcome in women with suboptimal thyroid function has been studied widely. 
Effects of OH have been more distinct56, although in many studies associations with poor 
obstetric outcome have also been found for women with SCH. Thyroid dysfunction is 
common in women of reproductive age, with SCH occurring in about 2-3% of all 
pregnancies57. However, this figure differs for women of different ethnicities and iodine-
intake39. In developed countries the most common etiology of SCH is autoimmune, while in 
developing countries this condition mostly occurs due to (severe) iodine deficiency39. 
Treatment of hypothyroidism with levothyroxine is currently advised for women with OH, 
while treatment of women with SCH (with or without TPO-Ab), as well as for euthyroid 
pregnant women with autoimmune antibodies (TPO-Ab) is still debated43,58 
Pregnancy loss is more prevalent in women with SCH, as has been described in multiple 
studies59-61. In a meta-analysis from Velkeniers et al. a beneficial effect of levothyroxine 
treatment was observed in the prevention of miscarriages in a population undergoing 
fertility treatment, with a number needed to treat of three55. Negro et al. have found that in 
euthyroid women with TPO-Ab, treatment with levothyroxine has beneficial effects on the 
reduction of miscarriages as well58. 
Complications during pregnancy such as gestational diabetes and pre-eclampsia are more 
common in women with SCH62-64. The relation between gestational diabetes and SCH can be 
biologically explained by the synergistic working of T3 and insulin. Increased insulin 
resistance is found in case of hypothyroidism, due to less glucose disposal in peripheral 
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tissues65. The insulin resistance found in patients with OH and SCH are similar, suggesting 
that the absolute levels of thyrothropine and thyroxine are of limited influence65. Pre-
eclampsia and hypertensive disorders in pregnancy in relation to SCH can be explained by 
endothelial cell activation, which is thought to be the cause of multi-organ involvement in 
pre-eclampsia64. There is evidence in non-pregnant individuals that SCH is associated with a 
number of cardiovascular conditions, such as coronary heart disease, which are caused by 
chronic endothelial cell damage66. Furthermore, a hypothyroid state leads to increased 
arterial stiffness, which in turn might lead to hypertensive disorders67,68. 
It has been indicated that maternal hypothyroxinemia is associated with poor fetal 
neurodevelopment and impaired psychomotor development in early childhood69. During the 
first half of gestation the fetus is totally dependent on maternal thyroid hormones. After this 
period the fetus begins to excrete its own thyroid hormones. However, maternal transfer of 
T4 continues to play an important role in fetal neurodevelopment throughout 
pregnancy70,71. 
There have been a few studies that address fetal growth in women with SCH, but those have 
shown conflicting results72-75. Perinatal mortality rates have not been studied widely in 
relation to SCH. However, there are some studies that have shown higher rates of fetal 
distress and even of higher perinatal mortality rates for women with (overt) 
hypothyroidism61,72,76. There have been no studies that have assessed meconium stained 
amniotic fluid in relation to SCH and besides, the association between MSAF and fetal 
distress itself remains controversial. CS-rates in women with hypothyroidism have been 
assessed in some studies, but the evidence for higher CS rates is scarce, especially for 
women with SCH72,76,77.  
 
Research questions 
The main questions of the current thesis are: 
1. Did the induction and Caesarean section rates  increase over the past decade in the 
Netherlands? 
2. Did a possible increase of Caesarean sections improve perinatal and maternal outcomes? 
3. Is suboptimal maternal thyroid function of influence on Caesarean section rates? 
4. Is suboptimal maternal thyroid function of influence on perinatal outcomes? 
 
Outline of the thesis 
In chapter 2 a general overview is given of induction- and CS-rates. Changes in trends in 
obstetric interventions have been studied over the past decade. We have determined 
whether possible trend changes of inductions and CS have influenced perinatal and maternal 
outcomes.  
The two main reasons to perform a CS during labor are failure to progress or (suspected) 
fetal distress.  
In chapter 3 the results of the analysis of 872 women in spontaneous labor were analyzed. 
We determined whether maternal thyroid function was of influence on the risks of 
instrumental vaginal deliveries or CS, mainly focusing on failure to progress.  
One of the historic determinants of fetal distress is meconium stained amniotic fluid. In 
chapter 4 the literature is reviewed regarding meconium stained amniotic fluid. Is meconium 
stained amniotic fluid indeed a sign of fetal distress? In this chapter the etiology of MSAF is 
discussed.  
In chapter 5 the association between maternal thyroid function and meconium stained 
amniotic fluid is studied in detail. An analysis of 1051 term pregnancies was performed. 
One of the main reasons for induction of labor is suspected fetal intra-uterine growth 
restriction, as this is one of the “big four” causes of perinatal mortality. In chapter 6 we 
determined whether suboptimal maternal thyroid function is a risk factor for small for 
gestational age offspring. 
Chapter 7 is a general discussion of this thesis. 
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Chapter 2  
Changing obstetric practice and effect on 
outcomes - is there a connection? 
 
 





Background – During recent years there has been a change in obstetric practice worldwide, 
leading to higher rates of inductions and Caesarean sections (CS). It is important to analyze if 
those changes have led to improved maternal and/or neonatal outcomes. In order to 
compare and contrast obstetric care across different units, a valid and uniform classification 
system should be used, such as the ‘Ten Group Classification System’. In this system all 
pregnant women are classified in one individual group, determined by different obstetric 
parameters. In the Netherlands such a system has not been implemented yet. 
We analyzed if there were changes in the induction and CS rates in the Netherlands during 
the past decade and whether this has led to any measurable alterations to perinatal and 
maternal outcomes. 
 
Methods – In this retrospective cohort study, all pregnancies ≥24 weeks from 2000 to 2009, 
were extracted from the Netherlands Perinatal Registry (PRN) database, a linked database 
consisting of almost all (>95%) hospital and home births in the Netherlands. Data from the 
current pregnancy, as well as the medical and obstetric history were retrieved. For all births 
the course of labor and delivery were recorded (spontaneous, induction or planned CS) and 
the mode of delivery. Furthermore, neonatal and maternal outcomes were collected. All 
pregnancies were classified according to the Ten Group Classification System. Differences 
were calculated using chi-square tests. For trend analyses the Cohran-Armitage test was 
used. 
 
Results – We found an increase in induction rates for nulliparous women over the years, 
from 16.5% in 2000 to 19.7% in 2009 (p<0.001). For multiparous women we did not find a 
statistically significant increase in induction rates. An overall increase in CS from 13.0% in 
2000 to 15.4% in 2009 was observed (p<0.001). The changes in induction rates and CS did 
not follow the same pattern. Postpartum hemorrhage showed a gradual increase over the 
years and was highest in groups 2 and 4 (single cephalic births with an induction or planned 
CS) (p<0.001). The overall number of stillbirths has dropped significantly by more than 100% 
(p<0.001).  
 
Conclusions – We found an increase in both induction rates and CS-rates over the past 
decade, although no direct association between inductions and CS was found. Maternal 
morbidity has increased over the years, while stillbirth rates have decreased. As a CS might 
also influence maternal morbidity in a possible subsequent pregnancy individualized care is 
very important. One should focus on a safe, vaginal, first birth. To analyze the effects of our 
changes in obstetric care, it is of uttermost importance to collect the best quality of data. To 
achieve this, a uniform classification system should be used, so that different obstetric care 





In recent years there has been a change in obstetric practice. The Term Breech Trial and 
Hypitat trial are examples of randomized controlled trials that have changed obstetric 
practice. The Term Breech Trial has resulted in an increase in Caesarean sections (CS) for 
breech presentations, whereas the Hypitat trial has led to increased induction rates in 
women with hypertensive disorders in pregnancy1-3.  Clinicians have a responsibility to 
practice ‘evidenced based medicine’ but they also have a responsibility to collect ‘the 
evidence’ to ensure that the best quality of care is being given to their patients4. It is 
therefore important to examine what the effect of changes in practice are and in particular 
to evaluate a possible benefit. The quality of obstetric care can be measured in several ways; 
for example through assessing rates of perinatal and maternal morbidity and mortality. 
Another attitude is to evaluate induction- and CS-rates. In general the best level of obstetric 
care can be defined by an optimal ratio, between the lowest level of maternal and neonatal 
morbidity and mortality, at the lowest level of intervention.  
During the last decades, a rising trend in CS-rates is observed worldwide, which has resulted 
in a discussion about appropriate CS rates4-6 and concerns that there is no additional 
perinatal health gain7,8 but that extra maternal morbidity and additional costs9 are involved. 
The consequences of high CS rates are higher maternal morbidity and mortality rates, both 
in the index pregnancy as well as in any subsequent pregnancies. There is a higher risk of 
placenta praevia or accreta, uterine rupture and necessity for peripartum 
hysterectomy8,10,11. The risk reduction for the fetus for perinatal asphyxia and birth trauma is 
often used to support  the decision to perform a CS12, but the perinatal health gain by 
performing a CS is subject to discussion7,8.  
There are many factors contributing to the increasing CS rates, including more obese women 
and higher maternal age. Those women are more likely to need a CS13,14. Furthermore, 
psychosocial factors (including CS on maternal request) or physical complaints and medico-
legal consequences play an important role15-16. Currently about 3% of the deliveries in the US 
are CS on maternal request17.  
One of the traditional risk factors of a CS has always thought to be induction of labor18,19. 
This has recently been questioned and opinion remains divided20-23. Fact is, that during the 
last decades, there has been an increase in the number of inductions of labor, both elective 
and for medical reasons23. Due to the large amount of current clinical trials studying the 
influence of induction of labor, on neonatal and maternal outcomes for many different 
factors (pre-eclampsia, postterm pregnancies), with overall favorable outcomes for 
induction, we expect a continuation of this rising trend of inductions3,24.  
An important parameter when analyzing obstetric care is perinatal mortality. The Peristat 
project, a European collaborative study in which indicators for perinatal health have been 
defined, has led to increased attention to perinatal mortality in the Netherlands in recent 
years, as the Netherlands had relatively high perinatal mortality rates25-28. Especially when 
compared to countries with a similar socio-economic status the Netherlands was in an 
unfavourable position regarding perinatal mortality.  
Another parameter of relevance when evaluating the quality of obstetric care is maternal 
morbidity, which can be defined by many outcomes measures. The most frequently used 
outcome for the definition of  maternal morbidity in the Netherlands is (severe) postpartum 
hemorrhage29. Therefore we have considered postpartum hemorrhage as an appropriate 
reflection of maternal obstetric outcome. Known risk factors for postpartum hemorrhage are 
induction of labor and CS and therefore we hypothesize that with increasing rates of these 
obstetric interventions, there will be  an increase in maternal morbidity.  
In order to compare and contrast obstetric outcomes between different countries and 
centres it is crucial to have a uniform classification system. In this way both low- and high-
risk pregnancies can be compared. The Ten Group Classification System (TGCS) or Robson 
Classification, has substantially contributed to the realization of appropriate comparisons of 
obstetric outcome between different institutions30. Each group is characterised by their own 
clinical identity and each group has its own characteristics and epidemiological importance. 
The 10 groups are totally inclusive, meaning that each patient can be placed in one group. 
The 10 groups are also mutually exclusive, meaning that each patient can only be classified 
in one group. In this way a valid comparison can be made when comparing  obstetric 
outcome in different institutes. In addition, the sizes and distribution of the groups 
themselves reveal much about the type of care provided in a particular obstetric care unit. 
Many facilities and countries have incorporated the TGCS in their routine clinical practice 
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and its value has been proven unequivocally31. In the Netherlands, such a classification 
system has not been implemented yet. It is important to note that although popularized for 
looking at Caesarean sections it can also be used to classify other obstetric outcome 
measures. 
Group  1 and 2 represent nulliparous women at term, with a single fetus in a cephalic 
position and group 5 represent women with at least one previous CS at term. It is generally 
agreed that for most populations group 1, 2 and 5 are the main contributors to the overall 
CS rate32,33. In order to stabilize or even reduce CS-rates, attention should mainly focus on 
these groups.  
We evaluated the effect of changes in obstetric care on perinatal and maternal outcome in 
the Netherlands comparing data from the Netherlands Perinatal Registry from 2000 to 2009. 
To the best of our knowledge this is the first study in which the unique obstetric system of 
the Netherlands is classified according to the TGCS. Our primary aim was to analyze if there 
were changes in the induction and CS rates in the Netherlands during this  decade. Our 
secondary aim was to assess whether those changes have resulted in any measurable 
alterations to perinatal and maternal outcomes.  
 
Methods 
In this retrospective cohort study all data were obtained from the Netherlands Perinatal 
Registry (PRN) database, which is a linked professional database of all pregnancies beyond 
16 weeks. Data from primary care (midwives and general practitioners) (LVR-1), secondary 
and tertiary care (LVR-2) and neonatologists (LNR) are collected in the dataset. More than 
95% of all approximately 180,000 annual deliveries (both hospital and home births) in the 
Netherlands are registered. This study was conducted with permission of the PRN, 
representing all professionals involved in the data registration.  
All pregnancies ≥24 weeks between 2000 and 2009 were extracted from the PRN database in 
a one record per mother format. Information on the current pregnancy and obstetric history 
were obtained, as well as data of the delivery and neonatal outcome, including stillbirths. 
For all births the course of labor and delivery was recorded (spontaneous, induction or 
planned CS) and the mode of delivery. The mode of delivery was considered spontaneous 
when there was no CS or instrumental vaginal delivery (ventouse or forceps). A planned CS 
was defined as a CS that was agreed on before labor, despite the fact that a woman could go 
into labor before the set date and have her planned CS at an emergency time. An emergency 
CS was defined as a CS during labor, when a CS was not planned during the course of 
pregnancy.  Postpartum hemorrhage (HPP) was defined as blood loss ≥1000mL. Perinatal 
mortality was defined as the stillbirth rate. All data were classified according to the Ten 
Group Classification System30 (table I). All deliveries in the Netherlands, including home 
births, were assessed.  
Table I – The Ten Group Classification System (TGCS)30 
Group Definition 
1 Nulliparous, single cephalic, ≥37 weeks, in spontaneous labor 
2 Combination of groups 2a and 2b 
2a Nulliparous, single cephalic, ≥37 weeks, induced labor 
2b Nulliparous, single cephalic, ≥37 weeks, planned CS 
3 Multiparous, single cephalic, ≥37 weeks, in spontaneous labor 
4 Combination of groups 4a and 4b 
4a Multiparous, single cephalic, ≥37 weeks, induced labor 
4b Multiparous, single cephalic, ≥37 weeks, planned CS 
5 Previous CS, single cephalic, ≥37 weeks 
6 Nulliparous breech 
7 Multiparous breech 
8 Multiple pregnancies 
9 Oblique lies 
10 Single cephalic, <37 weeks 
CS – Caesarean section 
 
For our primary outcome, to study the changes in induction and CS-rates, we have assessed 
all births between 2000 and 2009 in the Netherlands. Our secondary aim was to study the 
relationship between obstetric interventions (inductions and CS) and maternal and perinatal 
outcome. For the latter, we have only looked at groups 1-4, the single cephalic term births.  
In the other smaller and more diverse groups the relationship is probably more complex.  
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Statistical analysis was performed using the statistical software from SAS 9.3. Differences 
between categorical variables were analyzed using chi-square test. The Cochran-Armitage 
test was used for trend analyses. A p-value <0.05 was considered statistically significant. 
 
Results 
The CS-rates in all groups in 2000 and 2009 are shown in table IIA and IIB.  
Table IIA - Robson groups and contribution to Caesarean section rates in 2000 for all births in 
the Netherlands. Total number of births 182.493, overall Caesarean section rate was 13.0%. 
Missing values 1.3%. 
Groups Number of CS 
over total 
number of 













made by each 
group to overall 
CS rate (%) 
1 4681/59791 32.8 7.8 2.5 
2 3356/12873 7.1 26.1 1.8 
2a 2502/12019 6.6 20.8 1.4 
2b 854/854 0.5 100 0.5 
3 1277/64886 35.6 2.0 0.7 
4 2284/14358 7.9 15.9 1.2 
4a 711/12785 7.0 5.6 0.4 
4b 1573/1573 0.9 100 0.9 
5 3245/7358 4.0 44.1 1.8 
6 3543/5814 3.2 60.9 1.9 
7 1624/3564 2.0 45.6 0.9 
8 1197/3774 2.0 31.7 0.7 
9 534/557 0.3 95.9 0.3 
10 2028/9518 5.2 21.3 1.1 
 
Table IIB - Robson groups and contribution to Caesarean section rates in 2009 for all births in 
the Netherlands. Total number of births 171.964, overall Caesarean section rate was 15.4%. 
Missing values 1.7%. 
Groups Number of CS 
over total 
number of 












made by each 
group to overall 
CS rate (%) 
1 5302/54019 31.4 9.8 3.0 
2 4117/14410 8.2 28.6 2.4 
2a 3187/13480 7.8 23.6 1.8 
2b 930/930 0.5 100 0.5 
3 1403/61021 35.5 2.3 0.8 
4 3216/15418 8.8 20.9 1.8 
4a 842/13044 7.6 6.5 0.5 
4b 2374/2374 1.4 100 1.4 
5 3886/8172 4.8 47.6 2.2 
6 3471/4316 2.5 80.4 2.0 
7 1779/2457 1.4 72.4 1.0 
8 1251/3172 1.8 39.4 0.7 
9 550/599 0.4 91.8 0.3 
10 1880/8380 4.9 22.4 1.1 
 
In 2000 the overall CS-rate (planned and emergency) was 13.0% and it has gradually 
increased to 15.4% in 2009. In table IIa and IIb an overview is given for both the years 2000 
and 2009. In column II the absolute number of CS is shown, with the largest number in group 
1 (nulliparous women, in spontaneous labor at term, single cephalic fetus) for both years. In 
column III the group sizes are displayed. Groups 1 and 3 are the largest groups (spontaneous 
labor at term of a single cephalic fetus) in both years. There is an increase in induced labors 
and planned CS for at term women with a single cephalic fetus (group 2 and group 4). For 
the nulliparous women this increase is largest, from 7.1% to 8.4% of the population. In 
column IV the CS rates in each group are shown. The CS rates have increased for every group 
from 2000 to 2009 (except for group 9). The highest CS rates are seen for the non-cephalic 
groups (6, 7 and 9). In column V the contribution of each group to the overall CS rate is 
displayed. This is a combination of both the size of the group, as well as the CS-rate within 
that group. It enables us to see in which group the largest contributors to the overall CS-rate 
were found. In 2000 the largest contributors to the CS-rate were group 1, 2 and 6 
(nulliparous women at term, single cephalic fetus in spontaneous labor and induced and 
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nulliparous breeches at term). In 2009 the largest contributors to the absolute number of CS 
were groups 1, 2 and 5 (previous CS).  
In figure I the induction rates and CS rates for group 1 and 2 are displayed. The induction 
rates were calculated by dividing group 2A (induction) by the total number of women in 
groups 1 and 2 combined (all single cephalic nulliparous women at term). There is an 
increase in induction of term nulliparous women of 16.5% (12019/72664) in 2000 to 19.7% 
(13480/68429) in 2009 (p<0.001). The CS-rates have increased as well in group 1 and 2; from 
11.1% in 2000 to 13.8% in 2009 (p<0.001). The CS-rate for groups 1 and 2 remained stable 
between 2001-2005 with an increase afterwards. Overall, the CS rates show a statistically 
significantly rising trend over the years but with a different pattern than the induction rates. 
Maternal obstetric hemorrhage has steadily increased over the years, from 4.4% in 2000 to 
6.8% in 2009. Maternal obstetric hemorrhage (HPP) shows a statistically significantly rising 
trend over the years, with a similar pattern as the CS rates. Stillbirth rates in groups 1 and 2 
have been halved; from 2.0/1000 in 2001 to 1.0/1000 in 2009 (p<0.001).  
Figure I – group 1 and 2 as a cohort, all deliveries of nulliparous women with a single 
cephalic pregnancy at term. Induction and Caesarean section rates (both planned and 





In Figure II induction and CS-rates for groups 3 and 4 are shown. These are the multiparous 
women at term with a single cephalic fetus, without a previous CS. After an initial decrease 
of induction rates, an increase from 2006-2009 is noted (from 13.4% to 17.1%). The CS-rates 













2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Induction rate and CS-rate in nulliparous women at term (single cephalic pregnancy) 
related to stillbirth and maternal blood loss >1L (HPP) 
induction rate (%) HPP (%) 
CS-rate (%) stillbirth (‰) 
Figure I: all trends shown are statistically significant (P<0.001) 
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However, the trend of inductions and CS have a different pattern. Maternal HPP has shown a 
statistically significant increase from 3.1% in 2000 to 4.8% in 2009 (p<0.001). Stillbirths have 
decreased in this cohort of group 3 and 4 from 1.45/1000 in 2000 to 0.78/1000 in 2009 
(P<0.001). 
Figure II – cohort of group 3 and 4 combined, all deliveries of multiparous women without a 
previous CS, with a single cephalic pregnancy at term. Induction and Caesarean section (both 
planned and emergency) rates are outlined against perinatal mortality and maternal 




In figure III the maternal postpartum hemorrhage is shown in more detail. In all groups a 
statistically significant rising trend is observed (P<0.001). The highest HPP-rates are found in 












2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Induction and CS -rate in multiparous women at term without a previous CS  (group 3+4) outlined against antenatal 
mortality and maternal blood loss >1L (HPP) 
induction rate (%) HPP (%) CS-rate (%) stillbirth 
There is no significant trend for induction rates, all other trends are statistically 
significant (p<0.001). 
Figure III – postpartum hemorrhage (blood loss >1000mL) in the Netherlands for all single 



































Main findings  
The distribution within the ‘Ten Groups’ has changed over the years 2000-2009. An increase 
of inductions and planned CS was seen for both nulli- and multiparous (without a previous 
CS) women at term with a single cephalic pregnancy. The largest contributors to the 
absolute number of CS in 2009 were groups 1, 2 and 5. This is consistent with the current 
international literature32,33.  
The induction rates decreased up until 2006 for both nulli- and multiparous women. From 
2006 onwards a sharp increase in induction rates is seen, similar for nulli- and multiparous 
women. The increase in inductions as seen in our cohort, is also seen worldwide. The effect 
is largest from 2007 onwards, which could be the result of the preliminary results of the 
nationwide HYPITAT-study, which came out in 2007. This study showed that induction of 
labor is associated with improved maternal outcome and should be advised for women with 
mild hypertensive disease beyond 37 weeks gestation. However overall induction rates in 
the current study, are between 15-20%, which is generally lower compared to international 
induction figures34. 
There is ongoing controversy in the literature whether induction of labor after 37 weeks is 
associated with increased CS rate or not. Many studies describe an association between 
induction of labor and CS when compared to women in spontaneous labor18,19. However, 
Caughey et al. have introduced the concept that induction of labor should not be compared 
to spontaneous labor, but to expectant management instead20. When induction of labor is 
compared to expectant management, most studies don’t find increased odds for CS when an 
induction of labor is performed21-23.  Our study confirms this finding. From Figure I and II  it 
can be seen that the rising trend of CS rates follows a different pattern than the rise in 
induction rates. 
The overall CS-rate rose statistically significant from 13.0% to 15.4% between 2000 and 
2009. Compared to international literature, this CS-rate is low,  a well known feature of the 
Dutch obstetric system35. One of the reasons could be the strict division between midwife-
led care and obstetrician-led care. It is argued that midwifery-led care in general results in 
less obstetric interventions36. 
Postpartum hemorrhage has increased over the years and is higher in nulliparous women 
than in multiparous women. The overall international incidence of obstetric hemorrhage is 
6%, which is comparable to our results37. Known risk-factors are induction of labor, CS and 
nulliparity38. This is confirmed in our study where we found the highest incidence of HPP in 
the intervention groups, group 2 and 4 (Figure III).  However, from Figure I and II  it can be 
seen that the rising trend of HPP rates follows a different pattern than the rising induction 
rates. Since obstetric hemorrhage is a marker for the quality of labor management, it is 
interesting to note that in all groups there is an increase in HPP. However, there has been 
more attention for the registration of postpartum hemorrhage in recent years after a large 
nationwide trial, so the increasing trend could (partially) be due to improved registration29. 
Additionally the number of women at-risk for HPP has increased due to the increased 
incidence of inductions and CS.  
The overall number of stillbirths has dropped significantly by more than 100% (from 995 to 
441 cases (p<0.001)). Much attention has been gained in recent years to the relatively high 
perinatal mortality in the Netherlands, due to the European Peristat results26-28. There have 
been multiple initiatives to improve perinatal outcomes (e.g. teamtraining for obstetric 
emergencies and structural ultrasound scans at 20 weeks gestation)26. The stillbirth rate has 
decreased over the studied period and is now more comparable to other European 
countries. 
Strengths  
A major strength of this study is that in the Dutch perinatal database, there is an almost 
100% registration of all births in the Netherlands, leading to the evaluation of a large cohort 
of almost 2 million women. No women were double registered. Furthermore, there has been 
long experience in the validation of the linkage system between the different registration 
systems used (LVR-1, LVR-2 and LNR), resulting in a database of good quality35. 
Limitations   
In the study of large databases there is a risk of incomplete or incorrect data collection. The 
Ten Group Classification System could be used for validation of our database, as certain 
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figures are obligatory. For example group 9 should not exceed 0,5% of the total population 
and should have a 100% CS rate. Furthermore, there should be no missing values, as every 
woman should be placed in one individual group (totally inclusive system). In our database 
less than 2% of the data are missing, resulting in an almost complete database. In group 9 
the total figures are correct (less than 0,5%), but there is not a 100% CS rate, meaning that 
some women in this group are misplaced. Furthermore, the CS-rate in group 4 (single 
cephalic multiparous women without a previous CS) is relatively high, meaning that there 
might be women with a previous CS (group 5) inadvertently included in group 4. 
Another limitation is that in this observational cohort study, trends are analyzed. One of the 
main methodological problems is that (planned) induction or CS are not compared to 
expectant monitoring. This is one of the main challenges when analyzing the effect of 
obstetric interventions20. Therefore no direct causal conclusion can be drawn from this 
study: increased induction and CS-rates have not necessarily influenced perinatal mortality 
and maternal morbidity directly. Because of the retrospective design of the study, we could 
not correct for a possible change of attitude over time. Women and caregivers are 
increasingly less tolerant of adverse fetal outcomes, and, in the belief that CS will decrease 
the likelihood of this eventuality, tend to undergo CS more frequently.  
Another limitation is that for the analysis of maternal outcome maternal mortality was not 
considered. The most important cause of maternal mortality in the Netherlands used to be 
pre-eclampsia39. However, since the introduction of the results of the nationwide HYPITAT-
study, maternal outcome improved and pre-eclampsia is now no longer the first cause. 
Severe maternal morbidity can therefore be reflected by HPP.  
Future expectations  
For the future: we hypothesize that induction rates will increase further. We don’t expect 
the same rise in CS or HPP. It is of great importance to evaluate the effect of obstetric 
interventions to be able to provide the best quality of care. In order to make international 
comparisons, monitoring obstetric interventions and outcomes should be done by a uniform 
classification system, such as the TGCS ( Ten Group Classification System). 
Conclusion  
In our cohort there is no direct association between induction rates and CS-rates. Stillbirths 
have decreased with higher induction and CS-rates, but at the same time there has been an 
increased incidence of maternal obstetric hemorrhage. Maternal morbidity due to increased 
CS is not only of importance in the index pregnancy, but also in subsequent pregnancies, so 
management should be individualized and specific attention should be drawn to a safe 
vaginal birth for nulliparous women. It is of great importance to evaluate the effect of 
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Chapter 3  
High-normal maternal TSH and low-normal 
maternal FT4 are associated with a higher 
operative delivery rate in low-risk pregnancies:     
a prospective cohort study. 
 
 
Monen L, Pop VJM, Hasaart TH, Wijnen H, Oei SG, Kuppens SMI 




Background – The increasing number of operative deliveries is a topic of major concern in 
modern obstetrics.  Maternal thyroid function is of known influence on many obstetric 
parameters. Our objective was to investigate a possible relation between maternal thyroid 
function, and operative deliveries. Secondary outcome was to explore whether thyroid 
function was related to specific reasons for operative deliveries.  
Methods – In this prospective cohort study, low-risk pregnant Caucasian women were 
included. Women with known auto-immune disease, a pre-labor Caesarean section, 
induction of labor, breech presentation or preterm delivery were excluded. In all trimesters 
of pregnancy the thyroid function was assessed. Differences in mean TSH and fT4 were 
calculated using t-test. Mean TSH and fT4 levels for operative deliveries were determined by 
one way ANOVA. Repeated measurement analyses were performed, adjusting for several 
confounders.  
Results - At 36 weeks gestation women who had an operative delivery had a significantly 
higher mean TSH (1.63mIU/L versus 1.46mIU/L, p=0.025) and lower mean fT4 (12.9pmol/L 
versus 13.3pmol/L, p=0.007)) compared to women who had a spontaneous delivery. Mean 
TSH was significantly higher (p=0.026) and mean fT4 significantly lower (p=0.030) throughout 
pregnancy for women with an operative delivery due to failure to progress in second stage 
of labor, compared to women with a spontaneous delivery or operative delivery for other 
reasons, corrected for BMI, parity, and maternal age. 
Conclusions – High-normal TSH and low-normal fT4 are associated with more operative 
vaginal deliveries and Caesarean sections (especially due to failure to progress in second 
stage of labor), possibly to be explained by less efficient uterine action. 
Introduction 
Increasing rates of Caesarean Sections (CS) is a topic of major concern in obstetrics. Both the 
incidences of planned and emergency CS are rising, without necessarily better neonatal 
outcomes1,2. Operative vaginal deliveries (OVD) have shown a slowly decreasing trend, but 
OVD are still common, especially in nulliparous women. Maternal morbidity and mortality 
rates are higher for women with a CS or OVD2,3. Many studies have been performed to 
determine risk factors associated with operative deliveries. The main risk factors for CS and 
OVD are nulliparity, induction of labor, increasing maternal age, abnormal position of the 
fetus, high maternal body mass index (BMI) and previous CS4-6. Most CS and OVD are 
performed due to failure to progress, especially in nulliparous women6. The main reason is 
inefficient uterine action and to a lesser extent cephalopelvic disproportion. In fact, efficient 
uterine action is more and more considered as the key to normal delivery7,8.  
In previous studies it has been demonstrated that suboptimal maternal thyroid function is 
associated with adverse pregnancy outcomes9-12. Women with suboptimal thyroid function; 
mainly those with TPO-antibodies (thyroid-peroxidase-antibodies), are at risk for miscarriage 
and preterm birth9,10. Furthermore, there is evidence that high maternal TSH might interfere 
with normal  obstetric outcome at term, with higher incidences of small for gestational age 
neonates11, gestational diabetes10 and meconium stained amniotic fluid12. 
Little research is done into the relation between maternal thyroid function and uterine 
contractions. However, there is some evidence that suboptimal maternal thyroid function 
might be associated with more breech presentations, possibly due to increased stiffness of 
the myometrium13. This increased stiffness in patients with suboptimal thyroid function has 
been demonstrated in previous research in vascular smooth muscle cells as well14,15.  
In the current study we evaluated a possible relationship between suboptimal maternal 
thyroid function and inefficient uterine action at term. Primary outcome was to investigate a 
possible relation between maternal thyroid function and incidence of CS and OVD. 
Secondary outcome was to explore whether thyroid function was related to specific reasons 
for operative deliveries: due to fetal distress or failure to progress. In order to create a 
representative low-risk group we excluded the women at high risk for operative deliveries 




Design and participants 
During a period of two years, 1702 women who booked for antenatal visits at 12 weeks 
gestation were followed in five community midwife practices in the vicinity of Eindhoven 
(the Netherlands). Only Dutch Caucasian women (n = 1507) were eligible to avoid language 
problems and confounding factors of ethnicity. Seventy-nine percent (n = 1197) of the 
women gave informed consent; the non-responders did not differ from the responders 
regarding maternal age, educational level and parity (data not shown). Women on thyroid 
medication (n = 21), with a new diagnosis of hypothyroidism (n = 1) or hyperthyroidism (n = 
6) at screening, pregnant as a result of hormonal stimulation (n = 8), with multiple pregnancy 
(n = 8), and with Type 1 diabetes (n = 5) were excluded. Data were missing in 37 women. Of 
the remaining 1111 women a low-risk population was defined, with the exclusion of preterm 
deliveries, breech presentations and induction of labor. There were 60 women who 
delivered before 37 weeks gestation and 50 women who had a planned CS (45 for breech 
presentation). There were 5 more women with a fetus in breech presentation. Furthermore, 
there were 124 women who had an induction of labor. Therefore, data-analysis refers to 872 
women. The selection process is shown in figure 1 and the characteristics are shown in Table 
1. 
Delivery was considered an OVD when there was a ventouse or forceps delivery. In cases 
without CS or OVD, delivery was defined as spontaneous. The reasons for OVD and CS were 
classified as fetal distress, failure to progress in first stage of labor (prolonged dilatation) or 
failure to progress in second stage of labor (prolonged expulsion). Fetal distress was defined 
as a non-reassuring fetal heart rate with cardiotocography. This study was approved by the 
Medical Ethical Committee of Máxima Medical Centre in Eindhoven/Veldhoven. (METC 
project number: 0116). 
  








Pre-term delivery N=60 (1051) 
Primary CS N=50 (1001) 
Breech presentation N=5 (996) 
Induction of labour N=124 (872) 
Missing data N=37 (1111) 
Exclusion 
 
Women on thyroid medication N=21 (1176) 
Hypothyroid N=1 (1175) 
Hyperthyroid N=6 (1169) 
Pregnant after hormonal stimulation N=8 (1161) 
Multiple pregnancy N=8 (1153) 
Type I diabetes N=5 (1148) 
 
Egligible. N=1197 
1702 women (12 weeks gestation) 
Declined participation (N=505) 
Total included N=872 
1881 pregnant women 




TSH was measured in serum at 12, 24 and 36 weeks using a solid-phase, two site 
chemiluminescent enzyme immunometric assay (IMMULITE Third generation TSH, 
Diagnostic Products Corporation, Los Angeles USA). The inter-assay coefficients of variation 
were 5.0% and 4.4% at concentrations 0.22 mIU/L and 2.9mIU/L, respectively. The non-
pregnant reference range of TSH is 0.45 - 4.5 mIU/L. FT4 concentration was measured in 
serum at 12, 24 and 36 weeks with a solid-phase immunometric assay (IMMULITE Free T4). 
The inter-assay coefficients of variation for this technique were 6.7% and 4.4% at 
concentrations of 11.6 pmol/L and 31.5 pmol/L, respectively. TPO-Antibodies were 
determined in serum at 12, 24 and 36 weeks by means of the IMMULITE Anti-TPO-Ab kit. 
The inter-assay coefficients of variation for this analysis were 9% and 9.5% for 
concentrations of 40 kU/ml and 526 kU/ml, respectively.  The anti-TPO assay is standardized 
in terms of the International Reference Preparation for anti-TPO MRC 66/387.  Women were 
defined as TPO-Ab-negative when the titer was below 35 kU/ml at 12 weeks gestation. All 
measurements were performed in one laboratory. 
 
Statistical analysis 
Statistical analysis was performed using the Statistical Package of Social Science (SPSS, 19.0). 
TSH and fT4 concentrations were not normally distributed. However, because the cohort size 
of all subgroups was large (n > 30) we calculated differences in means (SD) of thyroid 
hormones concentration levels using Welch T-test (two-tailed).  Differences in prevalence 
were calculated by chi-square. We compared mean TSH and fT4 levels in different groups of 
etiology of non-spontaneous delivery using one way ANOVA. We compared the changes of 
mean fT4 and TSH throughout pregnancy in women with and without a spontaneous 
delivery using repeated measurement analyses, adjusting for confounders such as parity, 
BMI and maternal age.  
 
Results 
Table 1 shows that women who undergo an operative delivery have a higher pre-pregnancy 
BMI (26.3kg/m2 versus 25.0kg/m2) and have a longer gestational age (40.3 versus 39.8 weeks 
gestation). There were no statistically significant differences between a history of thyroid 
dysfunction in the family or the prevalence of positive TPO-antibodies. However, at 36 
weeks gestation (third trimester) women who had an OVD or CS had a significantly higher 
mean TSH and lower mean fT4 compared to women who had a spontaneous delivery (TSH 
1.63 mIU/L versus 1.46 mIU/L and FT4 12.9 pmol/L versus 13.4 pmol/L respectively).  
Table 1 - Characteristics of a group of 872 women who delivered at term (>37 weeks of 
gestation), comparing spontaneous deliveries and operative vaginal deliveries or secondary 
CS. Primary CS were excluded.   
 All deliveries (872) 
 
 
Mean (SD)      N(%) 
Spontaneous 
deliveries (747) 
Mean (SD)            N(%) 
Operative deliveries 
(125) 
Mean (SD)           
N(%) 
p-value 
t-test    
X2 
Age >35 yrs 30.5(3.6)  30.6(3.7)  30.0 (3.4)  0.08 
Low education  69 (8)  62 (8)  7 (6) 0.47 
BMI before 
pregnancy(kg/m2) 
25.2(4.3)  25.0 (4.2)  26.3(4.7)  0.002 
Primiparity  366(42)  268(36)  98 (78)  <0.001 
Miscarriage in 
obstetric history 
 164(19)  148(20)  16 (13) 0.06 
        






















































fT4 (pmol/L) 13.3 (2.2) 13.4 (2.2) 12.9 (2.1) 0.007 
        




 158(18)  137(18)  21 (17) 0.80 
        
Neonatal 
outcome: 
       
Term at delivery 
(wks) 
39.9(1.1)  39.8 (1.1)  40.3 (1.0)  <0.001 
Birth weight (gr) 3545(457)  3539(457)  3582(454)  0.33 
Male offspring  451(52)  380(51)  71(57) 0.20 
* Variables in bold are statistically significant (P<0.05).  
 
 
The different modes of delivery and the reasons for OVD and CS are shown in table 2.  
Table 2 – Mode of delivery in 872 women at term in whom labor started spontaneously. 
ANOVA analyses for influence of maternal thyroid function at every trimester on mode of 
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80.2% of the women had a spontaneous delivery and in 19.8% of the women an OVD or CS 
was performed. In 5.8% of the deliveries there was an OVD or CS due to failure to progress in 
first stage of labor, in 7.9% of the deliveries there was failure to progress in second stage of 
labor and 6.1% of all deliveries were terminated due to fetal distress. Mean fT4 and mean 
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TSH were compared between these subgroups using one way ANOVA. As shown in table 2, 
mean TSH was significantly higher at 12 weeks of gestation and at a 90% significant level at 
24 and 36 weeks gestation for women with an operative delivery due to failure to progress 
in second stage of labor. Mean fT4 was lower at a 90% significance level at the first and third 
trimester of pregnancy for women with failure to progress in second stage of labor.  
Subsequently, repeated measures ANOVA was performed to determine whether the 
changes of TSH and fT4 during pregnancy were associated with the mode of delivery and the 
different reasons for OVD or CS. As shown in figure 2, women who had an OVD or CS for 
failure to progress in the second stage of labor (delayed expulsion) had higher mean TSH 
levels (p=0.026) at all trimester adjusted for age, parity, BMI and gestational age, compared 
to women who had a spontaneous delivery or an OVD or CS for other reasons. 
Figure 2: The relation between mean TSH at all trimesters and the mode of delivery in 872 
term women in whom labor started spontaneously: women who had an operative vaginal 
delivery or Caesarean section because of prolonged expulsion had significantly higher mean 
TSH throughout gestation (repeated measures ANOVA, F = 3.1, p = 0.026.), adjusted for age, 
parity, gestational age and BMI. 
 
  
In figure 3 it is shown that women with an OVD or CS for failure to progress in second stage 
of labor, had a significant lower mean fT4 in all trimesters, adjusted for age, parity, BMI and 
gestational age, compared to women with a spontaneous delivery (p = 0.030) or OVD or CS 
for other reasons. There were no differences in maternal thyroid function between women 
who had a spontaneous delivery compared to women who underwent an OVD or CS for fetal 






In this study we found a significant association between high normal maternal TSH and low 
normal fT4 and the risk of operative delivery for women in spontaneous labor at term. Our 
cohort consisted of 872 Caucasian women with a low-risk pregnancy. Planned Caesarean 
sections, inductions of labor, preterm deliveries and breech presentations were excluded. 
Our cohort was representative in terms of thyroid function and obstetric outcome. We did 
find a higher incidence of TPO-Ab in our study (8.2%)  compared to another large cohort 
study in the Netherlands (5.6%)16, but this can be explained by the large number of African-
European women in their sample (up to 40%), in whom TPO-Ab occur less frequently17, while 
our sample included only Caucasian women. Mean TSH and fT4 levels of the current study 
are comparable to their sample. Obstetric outcome was proportionate to a large cohort 
study carried out in the Netherlands to analyse trends in obstetric interventions1. They 
found a CS rate of 7.5% for nulliparous women in spontaneous labor and an OVD rate of 
around 10% between 1993-2002, with an increase in CS rates over the years1. Our total 
operative delivery rate was 20%, for OVD and CS combined.   
The current study showed that women who undergo a CS or OVD had a higher pre-
pregnancy BMI and delivered at a later gestational age. This finding is consistent with 
previous reports8,18-20. We also found that women with an operative delivery for failure to 
progress in second stage of labor had higher mean TSH levels and lower mean fT4 levels 
throughout pregnancy, compared to women who delivered spontaneously or had an 
operative delivery for another reason. This finding was adjusted for maternal age, pre-
pregnancy BMI, parity and gestational age at time of delivery.  
Strength and limitations 
One of the main strengths of this study is the fact that maternal thyroid function was 
assessed prospectively throughout pregnancy at fixed time-intervals. Repeated 
measurement analysis was performed to assess changes in thyroid function within and 
between subjects. Furthermore, we corrected for important confounders, including BMI, 
which is one of the known risk factors for operative deliveries8,18,19. We have not used cut off 
values for suboptimal maternal thyroid function. We believe that this is a strength of this 
study, as there is considerable discussion about the proper cut off values and the definition 
of, for example, subclinical hypothyroidism in pregnancy21,22.  
A limitation of the study is the fact that this was an observational study and therefore no 
conclusions on causality of the associations can be drawn. Furthermore, no strict definition 
of fetal distress was used. Diagnosis of fetal distress was made on the basis of a non-
reassuring fetal heart pattern. As only healthy Dutch Caucasian women were analysed in this 
study, extrapolation of the results to women with other ethnicities or to high-risk pregnant 
women with for example hypertension or diabetes must be taken with caution. 
Interpretation 
Higher TSH and lower fT4 in this euthyroid sample were associated with higher operative 
delivery rates. However, TSH and fT4 were still in the normal ranges for all groups. In a large 
retrospective cohort study from Männistö et al. increased odds for CS (both prelabor and 
during labor) were found in women with primary hypothyroidism23. From that study 
however, it was not clear for what reasons the CS were performed. 
The main difference in the current study, according to maternal TSH and fT4, is found in OVD 
and CS due to failure to progress in second stage of labor. It is known that the most 
important factor in the expulsion of the fetus is the thickness of the myometrium and thus 
the strength of the contractions, despite the pushing efforts of the mother24. It has not been 
well established whether the spontaneous contractions are stronger during the second stage 
of labor than during the first stage of labor, but it is known that during Valsalva the power of 
the contractions is significantly higher in the second stage of labor25. With Valsalva it is not 
only smooth muscle cell contractions, but contractions of the skeleton muscles of the 
abdominal wall as well, that determine the expulsive power. It is well known that thyroid 
hormones are of influence on the contractile phenotype of skeletal muscles26. The most 
effective uterine action is needed in the second stage of labor and factors that are of 
influence on the strength of the contractions will therefore become most apparent during 
this stage.  
Calcium influx is necessary for excitation of the smooth muscle cells and therefore for the 
myometrial contractility required during labor. Parija et al. have demonstrated that 
hypothyroidism reduces calcium channel function in uterine tissue of the pregnant rat27. A 
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study from Corriveau et al. has found that the amplitude and time course of contractions is 
enhanced in patients treated with thyroid hormone compared to controls28. This suggests 
that thyroid function is of direct influence on myometrial contractility.  Besides the absolute 
strength of the contractions, it has also been found in vascular research that hypothyroidism 
leads to impaired smooth muscle cell relaxation, leading to increased arterial stiffness14,15. 
Moreover, women with failed external cephalic version had higher TSH values, probably 
because of impaired uterine relaxation which is essential for the breech baby to turn29. The 
combination of the strength of the contractions and the impaired relaxation of the 
myometrium might lead to less efficient uterine action in women with suboptimal thyroid 
function in this study. Future research should confirm this finding in a larger population and 
determine whether treatment of suboptimal maternal thyroid function leads to less failure 
to progress.  
 
Conclusion 
High normal maternal TSH and low normal maternal fT4 in this euthyroid sample, are 
independently related to higher rates of instrumental deliveries for women in spontaneous 
labor at term. Suboptimal maternal thyroid function is associated with more  OVD and CS 
especially due to failure to progress in second stage of labor, possibly to be explained by less 
efficient uterine action. The conclusions of this study are very relevant, as the increasing 
incidence of CS is one of the major concerns in modern obstetrics. Future research should 
confirm our findings and focus on determining the direct effect of maternal thyroid 
hormones on uterine contractions in vivo.  
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Introduction - despite the many efforts to study the (patho)physiology of meconium release 
before delivery, it still remains an indistinct subject. Some studies have reported a 
relationship between hypoxia and meconium stained amniotic fluid (MSAF), whilst others 
have not. The most common association found however, is between MSAF and the term of 
gestation. 
Methods - MEDLINE, EMBASE and the Cochrane library were electronically searched. Papers 
about the (patho)fysiology of meconium stained amniotic fluid in English were included. 
Papers about management strategies were excluded.  
Results - different theories have been proposed including acute or chronic hypoxia, 
physiologic fetal ripening and peripartum infection.   
Conclusion - we suggest that meconium stained amniotic fluid should be regarded as a 
symptom rather than a syndrome becoming more prevalent with increasing term and which 
might be associated with higher levels of infection or asphyxia.  
Introduction 
As a result of passing of fetal colonic contents, meconium stained amniotic fluid (MSAF) can 
be observed in 7-22% of all deliveries at term1. Historically MSAF has been regarded as an 
indicator of fetal asphyxia. In 1962 Leonard has already suggested a possible relation 
between fetal anoxia, fetal distress, perinatal death and MSAF2. Since then, many studies 
have been performed to evaluate the clinical relevance of MSAF in terms of prediction of 
fetal asphyxia.  
Despite the many efforts to study the (patho)physiology of meconium release before 
delivery, it still remains an indistinct subject. Some studies have reported a relationship 
between hypoxia and MSAF, whilst others have not. The most common association found 
however, is between MSAF and the term of gestation. In post-date pregnancies incidences of 
MSAF of up to 40% have been described3.  
In this systematic review we want to give an overview of the aetiology and pathophysiology 
of MSAF. Until now, the presence of MSAF results in an increase of interventions during 
delivery, as described in most studies; perhaps due to more fetal distress, but definitely 




MEDLINE, EMBASE and the Cochrane library were electronically searched through May 2013. 
The search comprised the terms ‘meconium stained amniotic fluid’, ‘aetiology’, 
‘pathophysiology’, ‘fetal distress’ and related entry terms. In addition, reference lists of 
identified articles and related reviews were hand searched. Titles, abstracts and entire texts 
were searched for potentially relevant articles.  Papers were included when the aetiology or 
(patho)physiology of meconium stained amniotic fluid were analysed. Both human and 
animal studies have been included. Retrospective studies as well as prospective studies, 
reviews and experimental researches have been included (Table I). Publications about the 
management strategies were excluded. There was a language restriction to English. There 
were no restrictions concerning the year of publication. The most important reports on the 
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aetiology of meconium stained amniotic fluid are presented in table I. Based on the included 
papers, the aetiology of MSAF could be divided into three categories: fetal hypoxia, fetal 
ripening and peripartum infection.  
 
Results and discussion 
1. Hypoxia 
In many studies MSAF is related to poorer neonatal outcome4,7-12. This includes lower 
APGAR-scores and lower cord blood pH-levels. Furthermore, in some studies more neonatal 
admittance to intensive care units is described7,11 and more perinatal deaths7,9. This 
association is seen as a prove that hypoxia leads to more intra-uterine meconium release. 
One of the known risks of MSAF is the meconium aspiration syndrome (MAS). About 5% of 
the infants with MSAF develop MAS, which still has a mortality rate of 2.5% in the developed 
world and up to 35% in the developing world13,14. The lower APGAR-scores, the more 
admittance to a neonatal ICU and the higher perinatal death figures could therefore be an 
effect of MAS rather than that it supports the theory that fetal hypoxia leads to more MSAF. 
Lower pH-levels and thus more acidosis on the other hand cannot be related to MAS only 
and supports the theory of fetal hypoxia leading to MSAF. However, in some studies no 
differences in pH levels are found in case of MSAF15,16. 
In a study of Ciftici et al. in rats, the aortas were clamped to effectuate hypoxic stress; none 
of the animals released meconium17. Therefore the authors suggested that the association 
between MSAF and poor neonatal outcome might be due to reduced clearance of 
meconium, rather than due to increased meconium release17. Furthermore they performed 
sympathectomy in animal models and then put those animals in a hypoxic environment. 
Compared to controls, there was no meconium release in the sympathectomised animals, 
but all animals in the control group did defecate after the hypoxic event. Furthermore, 
meconium by itself can have a vasoconstrictive effect on the umbilical cord and lead to 
necrosis and ulceration of the cord18 which can result in more fetal hypoxia. This does not 
necessarily mean that more hypoxia leads to fetal meconium release. Therefore, we cannot 
determine the exact pathophysiologic mechanism underlying the association between MSAF 
and fetal hypoxia.  
In a small study, placentas from neonates with MSAF have been pathologically examined and 
placenta´s thickening of the basal membrane was observed and more apoptosis was found12. 
These findings have also been described in growth-restricted infants and placentas of infants 
with fetal distress and are therefore suggested to be ultra-structural changes to hypoxia. 
Small for gestational age is also an independent risk factor for meconium stained amniotic 
fluid19. In an experimental animal study it has been indicated that hypoxemic stress leads to 
reduced swallowing of meconium stained amniotic fluid, instead of more meconium 
release17. This might explain the association between more meconium stained amniotic fluid 
and poor perinatal outcome, but not in the pathophysiologic way as previously proposed.  
 
Chronic or acute hypoxia 
If MSAF is indeed associated with fetal distress the question is whether MSAF is related to an 
acute hypoxic event or if MSAF is a symptom of chronic distress. In some studies a 
distinction has been made between thin and thick meconium5,6; thick but not thin meconium 
stained amniotic fluid was associated with poor neonatal outcomes in one of them5, while 
the other study from Ohja et al. found the opposite effect6. This difference of effect might be 
related to the timing of the proposed hypoxic event, in which thin meconium stained 
amniotic fluid would represent chronic, while thick MSAF would, rather represent acute 
hypoxemic stress.  Thick meconium stained amniotic fluid has a higher risk of causing MAS, 
which could (partially) explain the differences in perinatal outcome. Erythropoetine (EPO) is 
a cytokine for erythropoiesis and is released in case of hypoxemia20. The peak of EPO is 12 
hours after the onset of the hypoxic event, suggesting that it is a marker for chronic hypoxic 
stress21. In several studies an association between fetal erythropoietin (EPO) levels and 
MSAF was found8,16,22. EPO has not only been related to MSAF, but to longer duration of 
pregnancy as well16. However, when corrected for gestational age, EPO still remained 
significantly associated with MSAF. The lactate-creatinine ratio (L/C ratio) in first passed 
urine of newborns has been used to indicate intra-partum asphyxia. In a study form Ojha et 
al. higher L/C-ratios have been found in those newborn born through thin meconium, but 
not thick6. Thin meconium might therefore be related to chronic hypoxic stress. In rats, 
MSAF was associated with increased action of corticotrophin releasing factor (CRF)23. CRF is 
part of the stress-hormone family. In adults, CRF is known for its effect on colonic motility24. 
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Increased colonic motility after CRF exposure, would suggest that meconium release is 
enhanced by acute hypoxic stress.  
In conclusion, both acute and chronic hypoxia have been related to MSAF.  
 
Primary MSAF versus new-onset MSAF 
In several studies a distinction has been made between primary and secondary MSAF25-27. 
MSAF is considered primary when there is meconium staining at the time of membrane 
rupture. MSAF is considered new-onset or secondary when the liquor changes from clear to 
meconium-stained during labor. Hiersch et al. have again studied the difference between 
primary and secondary MSAF. They have confirmed the association between secondary, but 
not primary, MSAF and adverse neonatal outcome, suggesting that a change in colour of the 
liquor might reflect fetal distress whereas primary MSAF is a sign of fetal ripening25. 
 
2. Fetal ripening 
Another explanation of MSAF is the physiologic ripening of the fetal gastro-intestinal tract. 
The most consistent association with meconium stained amniotic fluid is gestational 
age3,11,15,16,28. Meconium stained amniotic fluid is rare before 32 weeks of gestation and it 
mostly occurs in pregnancies 37 weeks and over23, although it has been described from 16 
weeks of gestation onwards 18. It is known that MSAF is subject to ethnic differences29,30. The 
incidence is increased more than 80% in African-American and African-European women30. It 
has been shown in over 122.000 pregnancies that the mean gestational age is also shorter in 
African women, indicating a possibility for enhanced ripening of the fetus29. This enhanced 
ripening increases the risk of MSAF. In 1996 Ciftci et al. have already proposed the theory 
that fetal defecation might be a physiologic phenomenon31.  They have performed several 
animal experiments in which they showed that non-stressed goats and rats do defecate in 





Meconium stained amniotic fluid has been independently related to peripartum infection 
(RR 1.28) and thick meconium has a stronger association than thin meconium32. Wen et al. 
have also indicated in a case-control study (N=200) that MSAF is related to a higher 
incidence of intra-amniotic infection33  which was supported in a small retrospective study 
from Chapman34. Meconium might inhibit normal bacteriostatic function of the amniotic 
fluid and result in intra-uterine infections1. In a large Cochrane review the effect of 
antibiotics on neonatal and maternal infection in MSAF was analyzed. A significant reduction 
in chorio-amnionitis was found, but there was no effect on neonatal sepsis, NICU admission 
or postpartum endometritis1.  
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Hypoxia Infection Maturation Number of subjects (N) 
and type of article 
Meis 1982 +/- - - N=128 cases, N=134 
controls. Case-control 
study. 
Wen 1993 - + - N=200. Retrospective 
case-control study. 
Chapman 1995 - + - N=200. Retrospective 
case-control study. 
Richey 1995 +/- - - N=56. Case-control 
study. No difference in 
cord pH were found, 
however elevated EPO 
levels 
Maymon 1998 + + - N=37085. Cross-
sectional cohort study. 
Piper 1998 - + - N=936. Cohort study. 
Sienko 1999 + - - N=4. Histologic study.* 
Ciftici 1999 +/- - - N=16. Rat study.* 
Jazayeri 2000 +/- - + N=203 (N=70 with 
MSAF). Higher EPO 
levels but no differences 
in cord pH or APGAR. 
Sheiner 2002 +/- - - Prospective study. 
N=586. (N=106 with 
MSAF). 
Ahanya 2005 + + + Review. 
Locatelli 2005 + - - N=19090. Cohort study. 
Ohja 2006 +/- - - N=52 cases, N=42 
controls. Case-control 
study. 
Modarressnejad 2006 + - - N=400. Prospective 
study. 
Oyelese 2006 - - + N=6403. Retrospective 
study. 
Lakshmanan 2007 + - - N=12 cases, N=12 
controls. Rat study.* 
Shaikh 2010 + - - N=250 cases, N=250 
controls. Cross sectional 
study. 
Balchin 2011 + - ++ N=499096. 
Retrospective study. 
Lee 2011 + - + N=4376. Retrospective 
cohort study. 
Brailovschi 2012 +/- - - N=204102. Case-control 
study to intrapartum 
death. 
Kumari 2012 + - - N=75. Observational 
study. 
Yurdakul 2012 + - - N=13 cases, N=24 
controls.  Histologic 
study.* 
Gun Eriyilmaz 2013 + - - N=40 cases, N=40 
controls. Cross sectional 
cohort study.  




Summary and conclusion 
A lot of research has been done into the (patho)physiology of meconium release. Some 
authors claim the association between fetal distress and meconium release and therefore 
suggest that it is a pathologic event, while others have found only an association between 
gestational age and MSAF and not with fetal distress, suggesting a more physiological role. 
Different theories have been proposed in the last years, including impaired swallowing of 
meconium after physiologic defecation in utero. Furthermore, meconium has been 
associated with higher levels of intra-amniotic infections. The meaning of MSAF still remains 
subject to discussion.  
In conclusion, we suggest that meconium stained amniotic fluid should be regarded as a 
symptom rather than a syndrome, becoming more prevalent with increasing term and which 
might be associated with higher levels of infection or asphyxia. Irrespective of the possible 
cause, MSAF increases the risk of the meconium aspiration syndrome and hence perinatal 
death. In order to interpret MSAF properly we believe that other symptoms should also be 
taken into account, such as (non) re-assuring intra-partum cardiotocography or the presence 
of maternal fever.  
Key points 
There are three major causes for meconium passage in utero, hypoxia, maturation and 
infection. 
 Hypoxic stress may lead to MSAF, due to enhanced meconium passage or decreased 
swallowing of the foetus. 
 MSAF might reflect both acute and chronic hypoxia. 
 Secondary MSAF, with a change in liquor colour during labor, is associated with 
poorer neonatal outcomes than primary MSAF. 
 MSAF is associated with fetal maturation, where gestational age is the most 
important predictor of MSAF. 
 MSAF is independently related to peripartum infections.  
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Background - Maternal thyroid dysfunction is of known influence on pregnancies in the 
preterm period. However little is known about its effect on term and post term pregnancies. 
Meconium stained amniotic fluid (MSAF) is known to occur preferentially in (post)term 
pregnancies.  
Aims – To assess a possible independent relation between maternal thyroid function and 
MSAF. 
Study design and subjects – 1051 women, in whom thyroid function was assessed at each 
trimester, were followed prospectively (delivery ≥37 weeks). We compared the difference in 
mean TSH and fT4 between women with (152) and without (889) MSAF using one way 
ANOVA. Thyroid function was assessed in subgroups regarding gestational age. Finally we 
performed multiple logistic regression analysis with MSAF as dependent variable and TSH as 
independent variable adjusting for various confounders. 
Results – Maternal thyroid function was not associated with the incidence of MSAF when 
analysing all deliveries >37 weeks. However, in the “at-risk” group for MSAF (>41 weeks), 
multiple logistic regression showed an independent relation between MSAF and TSH (O.R. 
1,61, 95%CI: 1.10-2.43). 
Conclusions – The present study shows that in women delivering ≥41 weeks of gestation, 
higher TSH is independently related to MSAF.  
Introduction 
Overt thyroid disease has since long been associated with poor fetal outcome, as miscarriage 
and preterm birth1,2. But also sub-clinical  thyroid dysfunction which is present in 
approximately 5% of pregnant women is related to the similar complications1. Although it is 
known that maternal thyroid function is crucial in fetal organ maturation3, little is known 
about the relation between thyroid function and fetal outcome in term and post-term 
pregnancies. To the best of our knowledge, a study in which maternal thyroid function 
(thyrothropine-stimulating hormone (TSH), thyroxine (fT4) and thyroid peroxidase antibody 
(TPO-Ab)) is followed prospectively during gestation and related to the occurrence of MSAF 
has not been published yet. Therefore, we investigated the occurrence of MSAF in a large 
cohort without a history of thyroid dysfunction, who were followed prospectively from 12 
weeks of gestation and in whom thyroid function was assessed at each trimester and who 
delivered at term. The study outcome was to investigate a possible independent relation 
between maternal thyroid function and the incidence of MSAF in those who delivered at 
term.  
    
Materials and methods 
Subjects 
Women 
During a period of two years, 1702 women who booked for antenatal visits at 12 weeks of 
gestation were followed in five community midwife practices in the vicinity of the city of 
Eindhoven (the Netherlands), known to be an iodine sufficient area4. In order to avoid 
language problems (several questionnaires were used) and possible confounding of ethnic 
origin, only Dutch Caucasian women (n = 1507) were invited to participate.  Seventy-nine 
percent (n = 1197) of the women signed a consent form; the non-responders did not differ 
from the responders with regard to age, parity, or educational level (data not shown).  
Women on thyroid medication (n = 21), diagnosed as clinically hypothyroid (n = 1) or 
hyperthyroid (n = 6) at screening, pregnant as a result of hormonal stimulation (n = 8), with 
multiple pregnancy (n = 8), and with Type 1 diabetes (n = 5) were excluded. This left 1148 
women eligible for participation who were followed up at 24 and 36 weeks of gestation. Of 
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these women, data were missing for 37 women. Of the remaining 1111 women there were 
60 women who delivered preterm leaving 1051 women who delivered at term. Therefore, 
data-analysis refers to these 1051 women of whom the characteristics are shown in Table I. 
This study was approved by the Medical Ethical Committee of Máxima Medical Centre in 
Eindhoven/Veldhoven. 
Assessments 
Thyrothropine stimulating hormone (TSH) was measured in serum at 12, 24 and 36 weeks 
using a solid-phase, two site chemiluminescent enzyme immunometric assay (IMMULITE 
Third generation TSH, Diagnostic Products Corporation, Los Angeles USA). The inter-assay 
coefficients of variation were 5.0% and 4.4% at concentrations 0.22 mIU/L and 2.9mIU/L, 
respectively. The non-pregnant reference ranges of TSH is 0.45 - 4.5 mIU/L.  
Free thyroxine (fT4) concentration was measured in serum at 12, 24 and 36 weeks with a 
solid-phase immunometric assay (IMMULITE Free T4). The inter-assay coefficients of 
variation for this technique were 6.7% and 4.4% at concentrations of 11.6 pmol/L and 31.5 
pmol/L, respectively. The non-pregnant reference range of fT4 is 10.3 - 25.7 pmol/L.  
TPO-Antibodies (TPO-Ab) were determined in serum at 12, 24 and 36 weeks by means of the 
IMMULITE Anti-TPO-Ab kit. The inter-assay coefficients of variation for this analysis were 9% 
and 9.5% for concentrations of 40 IU/ml and 526 kU/ml, respectively. The anti-TPO assay is 
standardized in terms of the International Reference Preparation for anti-TPO MRC 66/387. 
Women were defined as TPO-Ab-positive when the titer was > 35 kU/ml at 12 weeks of 
gestation. 
Table I  - Characteristics of a sample of 1051 women who delivered at term (>37 weeks 
gestation), 889 women without MSAF and 152 women in whom MSAF was diagnosed.  




















T    Chi2 
Age >35 yrs 30.5 (3.5)  30.6 (3.6)  30.0 (3.7)  0.04 
Low education  82 (8)  68 (8)  14 (9)  
Smoking (yes/no)  127 (12)  105 (12)  22 (14)  
Alcohol use (yes/no)  137 (13)  118 (13)  19 (13)  
BMI (kg/m2) 25.5 (4.6)  25.4 (4.6)  25.8 (4.4)   
Primiparity  482 (46)  399 (44)  83 (45)  0.03 
Family history thyroid 
dysfunction 
 184 (17)  159 (18)  25 (16)  
Miscarriage earlier in 
life 
 196 (17)  169 (19)  27 (19)  
Fetal distress  115 (11)  95 (11)  20 (13)  
Mean hours first 
stage of labour 
7.3 (6.2)  7.1 (6.1)  8.7 (6.9)  0.003 
        
Mode of delivery:        
Spontaneous  686 (65)  587 (65)  99 (65)  
After induction  150(14)  126 (14)  24 (16)  
Instrumental  97 (10)  82  (9)  15 (10)  
Caesarean section  118 (11)  104 (12)  14 (9)  
        
Thyroid function:        
12 weeks gestation:        
TSH mIU/L 1.23 (0.78)  1.22 (0.78)  1.29 (0.82)   
FT4 pmol/L 16.0 (2.3)  16.1 (2.1)  16.1 (2.4)   
TPO-Ab >35IU/mL  86 (8.2)  73 (8.0)  13 (9)  
        
24 weeks gestation:        
TSH mIU/L 1.42 (0.67)  1.35 (0.65)  1.41 (0.76)   
FT4 pmol/L 13.8 (2.0)  13.8 (1.9)  13.7 (1.8)   
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TPO-Ab >35IU/mL  74 (7)  65 (7)  9 (6)  
        
36 weeks gestation:        
TSH mIU/L 1.51 (0.74)  1.50 (0.73)  1.57 (0.75)   
FT4 pmol/L 13.3 (2.0)  13.3 (1.9)  13.2 (1.8)   
TPO-Ab >35IU/mL  67 (6)  59 (7)  8 (5)  
        
Neonatal outcome:        
Term at delivery 
(wks) 
39.9 (1.2)  39.7 (1.2)  40.4 (1.0)  <0.001 
Birth weight (gr) 3526 (483)  3511 (494)  3596 (425)  0.03 
Placental weight (gr) 623 (127)  618 (126)  648 (130)  0.01 
Male  558 (53)  478 (53)  79 (52)  
Chi2:  df = 1 
Welch T-test Bold data indicate p<0.05. 
 
Statistical analysis 
Statistical analysis was performed using the Statistical Package of Social Science (SPSS, 19.0). 
TSH and fT4 were not normally distributed. However, as the cohort size of all subgroups was 
substantial (n > 30), differences in means (SD) of thyroid hormones concentration levels 
were compared using Welch T-test (two-tailed)5. Differences of prevalence rates were 
calculated by chi-square. Also, we compared the difference in mean TSH and fT4 between 
women with and without MSAF using one way ANOVA. Thereafter we defined a group of 
women with high TSH at each trimester using the 97.5th percentile as cut-off and compared 
the prevalence of MSAF in these different sub-groups. Finally we performed multiple logistic 
regression analysis with MSAF as dependent variable and TSH as independent variable, 
adjusting for several confounders such as elevated titers of TPO-Ab at 12 weeks of gestation, 
parity, duration of first stage of labor, smoking status and alcohol intake during gestation 
and pre-pregnancy BMI.  
 
Results 
As can be seen in Table I, there were 152 (14.5%) women with MSAF who delivered > 37 
weeks. Women with MSAF were significantly younger, were significantly more often 
primiparous, and had neonates with a significantly higher birth and placental weight (P < 
0.001, Student-T-test). The mean TSH and fT4 were comparable in the two groups as was the 
case for the number of women with elevated TPO-Ab titers. The number of fetuses with fetal 
distress during labor was similar in both groups (determined by CTG and APGAR-scores). 
There were no differences in mode of delivery (spontaneous, instrumental) between the two 
groups (Table I). Life style habits were also similar in both groups. MSAF occurred 
significantly more often at higher gestational age. There were no significant differences of 
thyroid function throughout pregnancy, in relation to gestational age at delivery (data not 




It can be seen that the prevalence of MSAF increased from 3 /67 (4.4%) in women who 
delivered at 37 weeks of gestation to 57 / 257 (22%) in those who delivered at > 41 weeks of 
gestation. In women who delivered before 41 weeks of gestation, no differences were found 
in TSH and fT4 between clear and meconium deliveries (data not shown).  
However, as shown in figure 2, in women who delivered > 41 weeks of gestation (n=257), 
the mean TSH was significantly higher throughout gestation in women with a history of 
MSAF (n=57), compared to those women who delivered at the same period of gestation 
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without MSAF (n=200): [ANOVA, F(1256) =8.0, p=0.005]. For fT4 no differences were found 
throughout gestation [ANOVA, F(1.256)=0.98, p=0.34]. 
 
Figure 2 - Mean TSH scores in a group of 257 women who deliver > 41 weeks gestation, 
comparing those with (n = 57) and without ( n = 200) a history of MSAF. (ANOVA, F = 8.0, p 
=0.005).  
 
We finally performed several multiple logistic regression analyses. First we performed an 
analysis in the whole group with MSAF as dependent variable and TSH at the last trimester 
as independent variable, adjusted for: gestational age at delivery, maternal age, smoking, 
BMI, alcohol intake, education level, parity, sex of the baby and the occurrence of fetal 
distress during labor. The only factor that was statistically significant related to MSAF was 
gestational age at delivery: O.R.: 1.63 (95% CI: 1.39 – 1.96, p < 0.001). With every week of 
increasing gestational age (from 37 weeks on) the likelihood of MSAF increased with 63%. 
TSH at the last trimester was not related to MSAF. When we repeated the logistic regression 
analysis using the same model in all different groups according to gestational age at delivery 
as shown in figure 1, with MSAF as dependent variable and TSH as independent variable, 
adjusting for the same variables no relations were found between any of the factors in the 
model and MSAF in the group of women who delivered at 37, 38, 39 and 40 weeks of 
gestation (data not shown). We then performed a logistic regression analysis in the group of 
women who delivered > 41 weeks of gestation (n = 257) with MSAF as dependent variable 
and TSH at 36 weeks as independent variable, adjusting for the same variables. As shown in 
Table 2, every mIU/l higher maternal TSH at the last trimester was associated with a 61% 
higher likelihood of MSAF at delivery at or after 41 weeks of gestation. Also primparous 
women had an O.R. of 2 to have MSAF at this term of delivery. Fetal distress during labor 
and the duration of first stage of labor were not associated with MSAF. 
Table II  Multiple logistic regression analysis in 257 women who delivered > 41 weeks 
gestation with MSAF as dependent variable (n = 57) and high maternal TSH at 
36 week gestation as independent variable, adjusted for possible 
confounders. 
     O.R.     95% CI  P 
High maternal age    0.98  0.89 – 1.09  0.71 
Low education    1.68  0.43 – 6.56  0.45 
Any alcohol intake    0.69  0.24 – 1.96  0.46 
Duration of first stage of labour (hours) 0.98  0.92 – 1.03  0.43 
Primiparity     2.01  1.17 – 4.89  0.025 
Fetal distress during labour   1.12  0.35 – 2.38  0.86 
Female neonate    0.95  0.75 – 1.49  0.31 
Smoking      0.73  0.62 – 1.78  0.87 
BMI     1.01  0.94 – 1.08  0.81 
TSH mIU/l at last trimester   1.61  1.10 – 2.43  0.013 
MSAF: meconium stained amniotic fluid. 
Discussion 
In the current study, the incidence of MSAF was 2.2% in those who delivered at 37 weeks of 
gestation compared to 22% in those who delivered at >41 weeks of gestation which is in line 
with the literature6. Thyroid function (TSH/fT4/TPO-Ab) was not different in women 
delivering at term or post-term and also, no relation was found between maternal thyroid 
function and MSAF, when looking at all term and post-term pregnancies combined. 
However, the sample size of the current study enabled to perform analyses in different 
subgroups according to gestational age at delivery. In women who delivered >41 weeks of 
gestation, TSH at the last trimester was independently related to the occurrence of MSAF 
(O.R.: 1.61, 95% CI: 1.10 – 2.43). Moreover, in this “at-risk” group (>41 weeks) for MSAF, the 
MSAF women had significantly higher mean TSH at all trimesters compared to those without 
MSAF. The mechanism behind this association is still unclear. However, it is known that 
maternal thyroid function is important for optimal placental function7. As placental function 
decreases with increasing gestational age, suboptimal maternal thyroid function (as 
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reflected by high normal TSH throughout pregnancy) might have an additional negative 
effect on placental function8,9. As such, women at or over 41 weeks of gestation with higher 
TSH are at increased risk of MSAF.  
Also, elevated maternal TSH might directly impact uterine relaxation, thereby negatively 
affecting placental circulation and predisposing to fetal distress. Empirical evidence of such a 
direct effect is seen in vascular smooth muscle10,11. High normal TSH leads to increased 
arterial stiffness and impaired diastolic function which can be neutralized by thyroxine 
replacement12. The same mechanism could be true in the smooth muscle cells of the uterus. 
The fact that no association was found between MSAF and fT4, might be explained by the 
questionable reliability of fT4 measurements in late pregnancy13. Recently, the group of 
Cunningham showed an association between high TSH (sub-clinical hypothyroidism) and the 
occurrence of diabetes gravidarum, as well as hypertension during gestation, which also 
underlines the relevance of possible negative impact of high TSH during gestation on 
obstetric outcome14,15. 
The current study has several strengths. Firstly, because of the power of our large cohort we 
were able to look at different subgroups of women, according to gestational age. Secondly, 
TSH was assessed at all trimesters showing a persistent higher TSH level in those women 
delivering >41 weeks with MSAF.  Also, the upper limit of TSH during gestation was 6.2 mIU/l 
(table I), suggesting that we did indeed study a relatively healthy euthyroid sample.  
A limitation of the study is that fetal distress at birth – which, according to the literature, 
might be an important cause of MSAF - was assessed according to APGAR scores and not to 
other denominators (e.g. umbilical artery pH-assessment).  
Future research should confirm a possible relation between maternal thyroid function and 
MSAF, especially in those delivering at advancing gestational age with more objectively 
assessing of fetal distress.  
In conclusion, our current study shows that in women delivering ≥41 weeks of gestation, 





 Meconium stained amniotic fluid is known to occur mostly in post-date pregnancies 
(≥41 weeks). 
 In this study we found primiparity and high maternal TSH in the last trimester of 
pregnancy to be independent risk factors for the presence of MSAF in pregnancies 
≥41 weeks. 
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Objective - Small for gestational age (SGA) newborns constitute still a major cause of 
perinatal morbidity and mortality. Overt thyroid disease is a known cause of preterm birth 
and low birth weight but in its untreated condition it is rare today. In this study we 
investigated the possible relation between maternal thyroid function assessed in euthyroid 
women at each trimester and the incidence of term born SGA neonates. 
Design – A prospective cohort study was performed. 
Patients - Thyroid function was assessed at 12, 24 and 36 weeks gestation in 1051 healthy 
Caucasian women who delivered at > 37 weeks gestation.  
Measurements - One-way ANOVA was used to compare mean TSH and fT4 levels between 
women with SGA neonates and controls. Multiple logistic regression analysis was performed 
to adjust for known risk factors of SGA. 
Results – Seventy (6.7%) SGA neonates were identified and they were significantly more 
often born to women with a TSH >97.5th  at first and third trimester. Multiple logistic 
regression analysis showed that smoking (O.R: 4.4, 95% CI: 2.49 – 7.64), pre-eclampsia (O.R.: 
2.8, 95% CI: 1.19 -6.78) and TSH > 97.5th  percentile (OR 3.3, 95% CI 1.39 – 7.53) were 
significantly related to SGA. Maternal fT4 levels and TPO-Ab status were not associated with 
SGA offspring. 
Conclusions – Our data show that TSH levels in the upper range of the reference interval at 
different trimesters (3.0-3.29 mIU/L) are independently related to an increased risk of 
delivering SGA neonates at term.  
 
Introduction 
Intra-uterine growth restriction  is an important cause of perinatal morbidity and 
mortality1,2. Small for gestational age (SGA) neonates are predisposed to adult metabolic 
syndrome due to altered metabolic homeostasis3,4. Several determinants of SGA have been 
described such as: maternal age  
>35 years, smoking, pre-eclampsia, low pre-pregnancy BMI and primiparity2. Overt thyroid 
dysfunction has long been recognized as an important risk factor of preterm birth and 
miscarriage5-8. Suboptimal maternal thyroid function (sub-clinical hypothyroidism and 
elevated titers of thyroid peroxidase antibodies [TPO-Ab]) has been related to poor perinatal 
outcome as well9,10. Research into a possible association between maternal TSH and fT4 
levels, and SGA is scarce and has resulted in inconclusive data11,12. A recent paper of a large 
cohort from Rotterdam found a relation between high maternal fT4 during early gestation 
and SGA, with no effect for maternal TSH or TPO-Ab status13.  
 
The present study investigates the occurrence of SGA in a cohort of more than 1000 women 
without a history of thyroid dysfunction, who were followed prospectively throughout 
gestation with thyroid function assessment at each trimester. Primary outcome was to 
investigate the possible relation between the incidence of SGA in those who delivered at 
term and maternal thyroid function, at a cross-sectional level (each trimester). Secondary 
outcome was to find out whether this possible relation persisted after adjustment for other 
factors which are known to be related to SGA.     
 
Materials and methods 
Subjects 
Women 
During a period of two years, 1702 women who booked for antenatal visits at 12 weeks 
gestation were followed in five community midwife practices in the vicinity of Eindhoven 
(the Netherlands), known to be an iodine sufficient area14. In order to avoid language 
problems (several questionnaires were used) and possible confounding of ethnic origin, only 
Dutch Caucasian women (n = 1507) were eligible. Seventy-nine percent (n = 1197) of the 
women signed a consent form; the non-responders did not differ from the responders with 
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regard to age, parity, or educational level (data not shown).  Women on thyroid medication 
(n = 21), diagnosed as clinically hypothyroid (n = 1) or hyperthyroid (n = 6) at screening, 
pregnant as a result of hormonal stimulation (n = 8), with multiple pregnancy (n = 8), and 
with Type 1 diabetes (n = 5) were excluded. Data were missing in 37 women. Of the 
remaining 1111 women, there were 60 women who delivered before 37 weeks gestation (in 
whom 11 had SGA neonates). Therefore, data analysis refers to 1051 women. This sample 
included 14 (1.3%) women with low pre-pregnancy BMI according to WHO classification 
(<18.4). The selection process is shown in figure 1 and the characteristics are shown in table 
1. This study was approved by the Medical Ethical Committee of Máxima Medical Centre in 
Eindhoven/Veldhoven. 
Neonates 
The Netherlands Perinatal Registry (PRN) was used to define SGA neonates. In this 
registration system, >95% of all hospital and home births in the Netherlands are registered. 
The definition of SGA was based on population based birth weight percentiles using the 
lowest 10th percentile cut-off2,15. Although the cut-off for the definition of SGA and intra-
uterine growth restriction is arbitrary, in most large studies the lowest 10th percentile is 
used16,17. To define SGA appropriately birth weight is corrected for: gestational age, sex of 
the baby and parity.  




















TSH was measured in serum at 12, 24 and 36 weeks using a solid-phase, two site 
chemiluminescent enzyme immunometric assay (IMMULITE Third generation TSH, 
Diagnostic Products Corporation, Los Angeles, CA, USA). The inter-assay coefficients of 
variation were 5.0% and 4.4% at concentrations 0.22 mIU/L and 2.9mIU/L, respectively. The 
non-pregnant reference range of TSH is 0.45 - 4.5 mIU/L 
Free thyroxin (fT4) concentration was measured in serum at 12, 24 and 36 weeks with a 
solid-phase immunometric assay (IMMULITE Free T4). The inter-assay coefficients of 
variation for this technique were 6.7% and 4.4% at concentrations of 11.6 pmol/L and 31.5 
pmol/L, respectively. The non-pregnant reference range of fT4 is 10.3 - 25.7 pmol/L.  
79% signed consent form. N=1197 
Exclusion 
- Women on thyroid medication N=21 (1176) 
- Hypothyroid N=1 (1175) 
- Hyperthyroid N=6 (1169) 
- Pregnant afterstimulation N=8 (1161) 
- Multiple pregnancy N=8 (1153) 
- Type I diabetes N=5 (1148) 
Missing data N=37 (1111) 
Excluding pre-term delivery (<37 weeks) N=60  




TPO-Ab were determined in serum at 12, 24 and 36 weeks by means of the IMMULITE Anti-
TPO-Ab kit. The inter-assay coefficients of variation for this analysis were 9% and 9.5% for 
concentrations of 40 IU/ml and 526 IU/ml, respectively.  The anti-TPO assay is standardized 
in terms of the International Reference Preparation for anti-TPO MRC 66/387.  A woman 
with TPO-Ab titer > 35 kU/ml at 12 weeks gestation was defined as moderately 
immunologically compromised, while a woman with TPO-Ab titer > 100 kU/ml was defined 
as distinctly compromised, even if the titer fell during pregnancy. Women were defined as 
TPO-Ab-negative when the titer was below 35 kU/ml at 12 weeks gestation. All 
measurements were performed in one laboratory. 
Statistical analysis 
Statistical analysis was performed using the Statistical Package of Social Science (IBM SPSS 
statistics for Windows. Version 19.0. Armonk, NY: IBM Corp.). TSH and fT4 concentrations 
were not normally distributed. However, because the cohort size of all subgroups was 
substantial (n > 30) we were able to calculate differences in means (SD) of thyroid hormones 
concentration levels using Welch T-test (two-tailed)18. Differences of prevalence rates were 
calculated by chi-square. We compared the changes of fT4 and TSH means in women with 
and without SGA neonates by means of one-way ANOVA. Thereafter we defined a group of 
women with high TSH at each trimester using 97.5th percentile as cut-off and compared the 
prevalence of SGA in these different sub-groups by chi-square with Bonferroni correction for 
multiple testing. Finally we performed multiple logistic regression analysis with SGA as 




In our study, 70 (6.7%) SGA neonates  (<10th percentile) were detected, of whom the 
characteristics are shown in Table I. There were 42 (4%) and 23 (2.2%) SGA neonates using 
the 5th and 2.3rd percentiles, respectively. None of the women who were included after 12 
weeks gestation developed overt thyroid dysfunction throughout pregnancy.  
Table I: Characteristics of a sample of 1051 women who delivered at term (>37 weeks 
gestation), 981 women with neonates with normal or high birth weight (AGA/LGA) and 70 
neonates who were Small for Gestational Age (SGA). 




















T    Chi2 
Age 30.5 (3.5)  30.5 (3.6)  30.6 (3.6)   
Smoking (yes/no)  127(12)  105(11)  22(31) <0.01 
Alcohol use (yes/no)  137(13)  127(13)  10(14)  
BMI (kg/m2) 25.5 (4.6)  25.5 (4.6)  24.7 (4.6)  0.14 
Primiparity  482(46)  450(47)  32(46)  
Multiparity  569(54)  531(53)  38(54)  
Miscarriage earlier in 
life 
 196(17)  180(19)  16(22)  
Pre-eclampsia  59 (5.8)  52 (5.3)  7 (10) 0.10 
Thyroid dysfunction 
in family 
 184(17)  170(18)  14(20)  
        
12 weeks gestation:        
TSH mIU/L 1.23 (0.78)  1.21 (0.76)  1.42(0.99)  0.12 
FT4 pmol/L 16.0 (2.3)  16.1 (2.3)  15.9 (2.1)  0.63 
TPO-Ab >35IU/mL  86 (8.2)  66 (8.0)  5 (7.1)  
        
24 weeks gestation:        
TSH mIU/L 1.42 (0.67)  1.41 (0.69)  1.52(0.71)  0.13 
FT4 pmol/L 13.8 (2.0)  13.8 (2.3)  14.1 (1.8)  0.53 
TPO-Ab >35IU/mL  74 (7)  69(7)  4(5.7)  
        
36 weeks gestation:        
TSH mIU/L 1.51 (0.74)  1.50 (0.72)  1.65(0.98)  0.18 
FT4 pmol/L 13.3 (2.0)  13.3 (2.1)  13.4 (2.2)  0.75 
TPO-Ab >35IU/mL  67 (6.2)  63(6.4)  4(5.7)  
        
Neonatal outcome:        
Term at delivery 
(wks) 
39.9 (1.2)  39.9 (1.3)  39.8 (1.1)   
Birth weight (gr) 3526 (483)  3582 (447)  2753(259)  <0.001 
Placental weight (gr) 623 (127)  632 (124)  482 (78)  <0.001 
Male  558(53)  515(53)  43(61) 0.15 
Female  493(47)  466(47)  27(39)  
 
The range for TSH at 12 weeks was between 0.04 and 5.2 mIU/L, at 24 weeks between 0.3 
and 5.7mIU/L and at 36 weeks between 0.4 and 6.2mIU/L. For fT4 the range at 12 weeks 
gestation was between 9.1 and 26 pmol/L, at 24 weeks between 8.4 and 24 pmol/L and at 36 
weeks gestation between 7.2 and 23pmol/L. This indicates that the studies population 
maintained normal thyroid function throughout the whole gestation. 
Women with appropriate for gestational age (AGA) or large for gestational age (LGA) 
neonates smoked significantly less often (p<0.001). Also, the birth weight and placental 
weight were significantly higher in the AGA/LGA group (P<0.001, Welch-T-test). Gender was 
not significantly different in the SGA group compared with the AGA/LGA group. Although at 
a cross-sectional level at each trimester, the mean TSH was higher in the SGA group, this 
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difference was not significant. Mean fT4 was rather similar in both groups and so was 
elevated TPO-Ab. In figure 2, the relation between SGA neonates and changes of mean TSH 
(figure 2) throughout gestation is shown.  
 
 
Figure 2 -  Mean maternal TSH levels throughout pregnancy in relation to small for 






As shown, in both groups, mean TSH did increase towards end gestation but during all 
trimesters, the mean TSH in the SGA group remained significantly higher compared to the 
women with AGA/LGA neonates (p<0.001). For mean fT4, no differences were found 
between the two groups related to SGA (data not shown).  
We subsequently defined high TSH at each trimester using the group as its own reference 
using an upper reference limit of > 97.5th percentile. These cut-offs were 3.28 mIU/L, 3.0 
mIU/L and 3.29 mIU/L, at 12, 24 and 36 weeks, respectively. 
We defined a group of women who had a TSH > 97.5th percentile at least at one trimester 
(n=53). Within this group, there were significantly more SGA neonates born; 17% in the high 
TSH group (9) and 6% (61) in the remaining 998 women [RR 3.8 (95% CI 1.8-8.1)].  Of the 53 
women with a TSH > 97.5th percentile at least at one trimester, 20 (37.7%) had elevated TPO-
Ab titers at 12 weeks gestation, compared with 66 (6.6%) in the group of women below this 
cut-off (p<0.001). We subsequently used other cut-offs to define SGA. When the lowest 5th 
percentile was used, high TSH at the third trimester (>97.5th percentile) was significantly 
associated with SGA, OR: 4.5 (CI: 1.5-13.7, p=0.008) When we used the lowest 2.3rd SGA cut-
off, high TSH at the last trimester was associated with SGA but only at a 90% significance 
level: OR 3.8, 95% CI: 0.85-17, p=0.08).  
We finally performed multiple logistic regression analysis with SGA (10th percentile) as 
dependent variable and high TSH (>97.5th percentile) as independent variable, adjusting for 
possible confounders (Table 2).  
 
Table 2  Multiple logistic regression analysis with SGA as dependent variable and high 
maternal TSH during gestation as independent variable, adjusted for possible 
confounders in 1052 women who delivered at term (>= 37 weeks gestation). 
 Odds Ratio 95% CI P-value 
Maternal age > 35 years 1.03 0.96 – 1.09 0.42 
Low education  1.29 0.84 -  3.02 0.23 
Alcohol intake (yes/no) 1.07 0.52 – 2.19 0.84 
Work outside home 
(yes/no) 
0.88 0.44 – 1.55 0.56 
Primiparity 1.13 0.65 – 1.96 0.61 
Term of gestation at 
delivery 
1.01 0.83 – 1.23 0.81 
Female neonate 0.77 0.46 – 1.49 0.31 
Smoking 4.38 2.49 – 7.64 <0.001 
BMI 0.95 0.89 – 1.008 0.08 
High TSH* 3.31 1.39 – 7.53 0.007 
Thyroid dysfunction in 
family 
0.57 0.26 – 1.23 0.15 
Pre-eclampsia 2.84 1.19 – 6.78 0.018 
SGA: small for gestational age: birth weight in the lowest 10th percentile corrected for 
gender, parity and term at delivery 




As indicated, high TSH (> 97.5th percentile at one or more trimesters) (OR 3.31, 95% CI: 1.39-
7.53), the occurrence of pre-eclampsia (OR 2.8, 95% CI: 1.19-6.78) and smoking (OR 4.4, 95% 
CI: 2.49-7.64) were independently related to SGA. 
 
Discussion 
The current study, with a prospective design in which thyroid function was evaluated at each 
trimester in a cohort of more than 1000 euthyroid pregnant women who delivered at term, 
showed that TSH >97.5th percentile at any trimester was independently related to SGA (O.R.: 
3.3, 95% CI: 1.39 – 7.53), adjusted for confounders of SGA such as smoking and the 
occurrence of pre-eclampsia.  
The prospective design of the study enabled to show that women with SGA neonates had an 
increase of TSH throughout gestation at a level which was consistently higher and 
significantly different from those with mothers of appropriate or large for gestational age 
(AGA/LGA) neonates. In detecting an upper limit of TSH that was associated with an 
increased risk of SGA, the 97.5th percentile proved to be associated with an increased risk of 
SGA. This might suggest that the optimal upper limit of TSH, regarding SGA offspring, during 
gestation ranges between 3.0 - 3.29 mIU/L, depending on the trimester. Low levels of TSH 
and fT4 levels were not related to SGA. 
In our study population we found 6.7% SGA, which is slightly lower than expected for the 
<10th percentile. This could be explained by the fact that we only included healthy women 
and women who delivered at term. We found no differences in the SGA and AGA/LGA 
groups in terms of alcohol use, BMI, family history of thyroid dysfunction or term of delivery 
(table I). The only statistically significant difference that we found in the patient 
characteristics was smoking status and the occurrence of pre-eclampsia, which are known 
risk factors for SGA2,19,20. When comparing our cohort to the large recent study from 
Rotterdam, we see comparable figures regarding mean TSH and fT4, suggesting that we 
included a representative population13. We did find a higher incidence of TPO-Ab (8.2% in 
the first trimester compared with 5.6% in the study from Rotterdam), but this could be 
explained by the large number of African-European women in their sample (up to 40%), in 
whom TPO-Ab occur less frequent21.  
In previous studies the relationship between overt thyroid disease and SGA has been well 
established5-8. Studies about a possible relation between SGA and fT4 and TSH ranges in 
euthyroid women are scarce and have shown conflicting results9,11,12,22.  An explanation for 
these inconclusive findings is first, the different time of assessment of maternal thyroid 
function, which is important when relating it to SGA outcome. Moreover, different 
definitions for SGA (birth weight percentiles should be corrected for parity, sex and term of 
gestation) and different cut-offs have been used (<10th percentile and <2.3th percentile). 
Finally, a possible relation between maternal thyroid function and SGA should be adjusted 
for other important confounders, such as pre-eclampsia or smoking. 
Two studies have found no differences in maternal thyroid function in SGA neonates11,12. The 
sample size was, however, small in one study (N=89)11 and in the other study thyroid 
function was only assessed between 11 and 13 weeks of gestation12. By contrast, however, 
the study from Shields et al. had found an association between high maternal fT4 levels at 28 
weeks gestation and lower birth weight of the offspring. A 10% increase in fT4 resulted in 59 
g decrease in absolute birth weight (thus not necessarily SGA). A very recent, large cohort 
study from Rotterdam has endorsed the finding that high free T4 levels, in euthyroid 
women, but not TSH levels, are related to SGA13. However, in this study thyroid function was 
assessed only once at around thirteen weeks of gestation, so no prospective changes in 
thyroid function could be observed. Furthermore, in contrast to TSH assessment, there have 
been concerns about the reliability of the measurement methods used of free T4 levels in 
pregnancy23. Recently, the International Federation of Clinical Chemistry Working Group has 
set-up a procedure to standardize fT4 assessments24. This recently developed reference 
measurement system is a key advance towards improved standardization and clinical validity 
of free thyroid hormone measurements and should preferentially be implemented in future 
research25. The study from Rotterdam consisted of only 62,2% Dutch or other Western 
immigrants, which is substantially different from the general Dutch population26 and the 
current study in which only Caucasian women were included.  
Casey et al.9 showed in a retrospective study of over 15.000 pregnancies that there was a 
significant relation between higher TSH levels and poor obstetric outcome, which was not 
the case for low TSH or fT4 in upper or lower reference ranges. In a more recent study, the 
same group showed a relation between high TSH and the development of severe pre-
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eclampsia27.  Pre-eclampsia by itself is an independent risk factor for SGA2. In the current 
study this is shown as well, but even after adjustment for pre-eclampsia, the independent 
relation between high TSH and SGA persisted. Maternal thyroid function is important for 
fetal growth, due to the need of trans-placental passage of T425. Thyroid hormones enhance 
fetal growth by anabolic action on fetal metabolism and their influence on different growth 
factors (i.e. insulin-like growth factors)29. This might explain why in the current study, 
women with TSH in the upper reference ranges (suboptimal maternal thyroid function) were 
at risk to deliver term SGA neonates. Another explanation could be the role of thyroid 
hormones on placentation. Karagiannis et al. studied the role of thyroid hormones in 
placentation and found no association12. However, there is some evidence that high fT3 and 
fT4 levels do have a role in vascularization, proliferation and differentiation of the 
placenta30,31. A recent meta-analysis on levothyroxine treatment in women with subclinical 
hypothyroidism undergoing assisted reproductive techniques, has indicated that T4- 
replacement therapy is beneficial on pregnancy outcomes, possibly indicating a role for 
thyroid hormones on placentation as well32.  
The current study has several strengths. First, maternal thyroid function was assessed at 
each trimester enabling to look at the dynamic pattern of thyroid function changes during 
gestation in relation to SGA. Secondly, trimester specific upper limits of TSH were defined 
using generally accepted cut-offs of 97.5th percentiles. Thirdly, the upper limit of TSH during 
gestation was 6.2 mIU/L (table I), suggesting that the cut-offs of high TSH (> 97.5th 
percentiles) refer to women without severely high TSH. This means that the relation 
between higher TSH and SGA, is analyzed in a healthy euthyroid sample. Fourth, the 
definition of SGA was corrected for parity, sex and gestational age. In international literature 
different definitions of SGA are used, including ≤-2SD for gestational age (<2.3rd percentile)32, 
<3rd percentile and <5th percentile33, but most recent studies have used the <10th percentile 
definition as described previously. Furthermore, a recent survey in Ireland has identified that 
the opinion of most clinicians is that the lowest 10th percentile should be used to define 
intrauterine growth restriction.17 The best definition however, is based on customized 
percentiles and individual growth potential, to rule out the effects of, for example, 
ethnicity15. As only Dutch Caucasians were included in our study population, population 
based percentiles from the Netherlands perinatal registry are appropriate for the definition 
of SGA in our cohort. Finally, factors that are known to be related to SGA such as smoking 
and pre-eclampsia, were also independently related to SGA in the current study, suggesting 
that the women in this cohort refer to a representative sample.     
Several limitations of the study need to be mentioned. First we did not consider iodine 
status. A study from Alvarez et all. showed that low iodine levels in maternal urine are 
related to a higher incidence of SGA34. However, the iodine intake in our region has recently 
been shown to be generally sufficient14. Moreover, results of congenital heel screening in 
886 neonates born in the sample showed 13 (1.5%) newborns with a TSH >5 mIU/L, a figure 
which is below 3%, a generally accepted cut-off showing sufficient iodine intake at a 
population level35,36. Furthermore, although the number of women who were prospectively 
followed was relatively large, the absolute number of SGA was only 70. Finally, our 
population was a selected cohort of women without medical disease, such as hypertension 
or diabetes and all from the same ethnic origin. The results found should therefore be 
validated in cohort studies with women from different ethnic backgrounds. Also, in future 
research one should be aware to obtain appropriate trimester specific reference levels of 
the TSH cut-offs, as those can differ for different methodology used at different centers and 
in women with different iodine intake. 
In conclusion, the current study supports the evidence that TSH levels in euthyroid women 
at different trimesters in the upper range of the reference interval (3.0 to 3.29 mIU/L) are 
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Chapter 7  
General discussion and future perspectives 
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In this thesis the evaluation of obstetric interventions over more than one decade and the 
association between suboptimal maternal thyroid function and several obstetric outcomes 
have been discussed. 
 
Obstetric interventions 
In chapter 2 we have analyzed the obstetric interventions and outcomes in a ten-year period 
in the Netherlands. The answers to research questions 1 and 2 – “Did the Caesarean section 
rates and induction rates increase over the past decade in the Netherlands?” and “did the 
increase in Caesarean sections improve perinatal and maternal outcomes?” – are found in 
this chapter. We have used the Ten-Group Classification System, which is a generally 
accepted classification system to compare and contrast figures regarding CS and other 
obstetric outcomes1,2. We found an increase in CS and induction rates in the period from 
2000-2009, which is comparable to international literature. Traditionally obstetric 
interventions are low in the Netherlands and despite the increase that is seen, the figures for 
CS and inductions remain low when compared to other developed countries3. One of the 
major reasons is the large proportion of midwifery-led care, which is a known protective 
factor against obstetric interventions4. We observed an improvement in perinatal and 
antenatal mortality and in perinatal morbidity (defined by less neonates with low Apgar-
scores) in the studied period. On the one hand, this could be due to increased interventions. 
On the other hand many initiatives have been implemented in the Netherlands over the past 
decade, as a consequence of the unfavorable position of the Netherlands in the European 
Peristat study to perinatal mortality5,6. The improved perinatal outcomes could thus be 
related to a combination of more interventions and non-invasive improvements (e.g. more 
team training for obstetric emergencies)7. Contrary, we found an increase in maternal 
morbidity, reflected by a gradual increase in postpartum hemorrhage (HPP) in the 10-year 
study period. Partially this could be due to better registration after a nationwide study to 
severe maternal morbidity8, but it could also be due to more obstetric interventions, as both 
inductions and CS are known independent risk factors for HPP9.  
The association between inductions and increased odds for CS are currently being 
debated10,11. In our study no direct association was found between increased inductions and 
CS.  
As CS do not only influence maternal and neonatal health during this pregnancy, but also in a 
possible subsequent pregnancy we suggest to balance the risk-benefit ratio thoroughly for 
every (planned) CS. It is of uttermost importance to try and avoid the first CS -when a 
woman has the highest chance of a vaginal delivery-  to stabilize or even decrease the CS-
rate nationwide12. As the relation between inductions and CS is not yet fully determined the 
outcome of currently ongoing large randomized trials might give more decisive answers 
whether to perform an induction of labor or not for specific situations. 
 
Obstetric interventions and the thyroid 
To answer research question 3 – “Is suboptimal maternal thyroid function of influence on 
Caesarean section rates?” – we have analyzed a group of low-risk women prospectively. We 
have found that suboptimal maternal thyroid function is indeed associated with more CS and 
operative vaginal deliveries at term, as described in chapter 3. Mean TSH was significantly 
higher (p=0.026) and mean FT4 was significantly lower (p=0.030) throughout the entire 
pregnancy in women with an operative delivery for failure to progress in second stage of 
labor, when compared to women with a spontaneous delivery or operative delivery for a 
different reason, although the mean levels of TSH and FT4 remained within the normal 
reference ranges. How can this finding be explained? 
It is known that the most efficient uterine action is needed in the second stage of labor and 
that it is mostly the thickness of the myometrium that determines the effectiveness of the 
contractions, despite the pushing maneuvers of the mother13,14. This means that probably 
not the skeleton muscles of the abdominal wall are most important for effective expulsion of 
the fetus, but the smooth muscle cells of the myometrium. We argue that the impaired 
smooth muscle cell function in women with suboptimal thyroid function is binary. Firstly, 
there is evidence for impaired relaxation of smooth muscle cells leading to increased arterial 
stiffness in hypothyroid women in vascular research15,16. Secondary, there is evidence for 
decreased contractions of smooth muscle cells in hypothyroidism. Both impaired relaxation 
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and contraction are thought to be due to impaired functioning of calcium channels as is seen 
in the uteri of hypothyroid rats17,18.  Furthermore, when treatment  with T3 hormone is 
given, the amplitude and duration of myometrial contractions is enhanced19. However, TSH 
receptors have not been identified on the myometrium of the uterus yet. Future research is 
needed to investigate if there indeed is a TSH-receptor on uterine tissue, which could then 
be directly targeted in case of for example dystocia during labor. 
Meconium stained amniotic fluid and fetal distress 
In chapter 5 we have discussed the association between high maternal TSH and meconium 
stained amniotic fluid (MSAF) to answer the first part of research question 4 – “Is suboptimal 
maternal thyroid function of influence on perinatal outcomes?”. We found that high normal 
TSH at 36 weeks gestation was an independent risk factor for the presence of MSAF in 
pregnancies ≥41 weeks gestation (n=157) with an O.R. of 1.61, corrected for multiple 
confounders such as fetal distress, the duration of the first stage of labor and maternal age. 
We only found an association for pregnancies beyond term (≥41 weeks), but it is known that 
advancing gestational age is the most important determinant of MSAF20-22. To our 
knowledge our study is the first to describe this association and therefore the mechanism 
behind this association is still unknown. However, the concept of increased myometrial 
stiffness, as described in the section above, might be one of the reasons for the observed 
association. It is suggested that the increased myometrial stiffness might lead to impaired 
placental circulation, thereby enhancing fetal distress. Besides, it is known that maternal TSH 
is necessary for normal placental development23. As the function of the placenta decreases 
with advancing gestational age24, the suboptimal maternal thyroid function might be of an 
additional negative influence on the placenta, thereby further augmenting fetal distress. 
However, in our study we did not find differences for fetal distress (as determined by a non-
reassuring fetal heart rate pattern) or operative deliveries in the MSAF or non-MSAF groups.  
In the review presented in chapter 4 we have discussed the controversy about the 
association between MSAF and fetal distress. Some studies did find an association between 
lower Apgar-scores, lower cord-blood pH’s and biochemical effects of hypoxia25-27. The 
results however are conflicting across different studies28. It might therefore be possible that 
the results described in chapter 5 do reflect fetal hypoxia and therefore defecation in utero 
due to increased stiffness of the myometrium, but that it did not lead to severe fetal distress 
with the need for obstetric interventions. Future research should determine whether our 
finding is consistent and which underlying mechanisms could be responsible for this 
association. Furthermore, we did not have an objective form of describing fetal distress. 
Ideally cord pHs should be measured alongside Apgar-scores in future research. 
Small for gestational age 
In chapter 6 we have discussed the results of a prospective cohort study to maternal thyroid 
function and small for gestational age offspring at term, to answer the second part of 
research question 4 – “Is suboptimal maternal thyroid function of influence on perinatal 
outcomes?”. It was found using multiple logistic regression analyses that there were three 
independent risk factors in our cohort of low-risk pregnant women for getting SGA neonates; 
smoking (O.R. 4.4), preeclampsia (O.R. 2.8) and high TSH at any trimester (O.R.3.3). High TSH 
was defined as the ≥97.5th percentile at any trimester, with the study population as its own 
reference. The cut-offs for high TSH in our study were 3.28mIU/L, 3.0mIU/L and 3.29mIU/L 
at the three trimesters respectively. This is comparable to international literature and 
suggests we performed our study in a representative study population29. FT4 and TPO-
antibodies were not associated with SGA. Preeclampsia and smoking are known 
independent risk factors for SGA offspring30. The relation between sub-clinical 
hypothyroidism (SCH) and small for gestational age offspring or neonates with low birth 
weight (not corrected for parity, gestational age and sex of the baby) has been confirmed by 
some authors, but has been denied by others31-34. A reason for the conflicting results could 
be found in the measurements of the thyroid hormones (methodology and timing), as well 
as in the definition of SGA (corrected for confounders, different percentiles used). The 
association between thyroid function and SGA found in some studies, including ours, could 
be explained by the role of thyroid hormones in placentation. In in vitro and animal studies a 
role for thyroid hormones has been demonstrated in placentation, as vascular endothelial 
growth factor (VEGF) and epidermal growth factor expression are enhanced if thyroid 
hormones are administered35,36. As placental dysfunction is the most common cause of IUGR 
impaired placentation might be of great importance to the subject. However, SGA was not 
only associated with suboptimal maternal thyroid function in the first trimester when 
104 
 
placentation took place. The association throughout pregnancy could be explained by the 
fact the transplacental T4 is needed for fetal growth throughout pregnancy. High TSH might 
actually reflect poor transfer of maternal FT4 through the placenta.  
Conclusions of this thesis 
The two main topics of this thesis are the increase in CS and induction rates in the 
Netherlands and the negative influence of suboptimal maternal thyroid function on obstetric 
outcomes.  
Regarding the first topic, we came to the conclusion that CS rates and induction rates in the 
Netherlands did indeed increase during the past decade in the Netherlands, but CS are still 
low compared to international figures. Perinatal mortality rates have improved during the 
past decade. Furthermore, Apgar-scores <5 decreased in our study. Contrary, we saw an 
increase in maternal postpartum hemorrhage, the most important determinant of maternal 
morbidity. 
We have shown that maternal thyroid function might be of influence on CS-rates in the 
Netherlands due to failure to progress in second stage of labor. Increased odds for CS are 
found in women with suboptimal thyroid function in our cohort. Furthermore, there is an 
association with more small for gestational age offspring and more meconium stained 
amniotic fluid in offspring from women with high normal TSH. Meconium stained amniotic 
fluid does not necessarily mean that there has been fetal distress, but despite the causes, 
there is an increased risk of perinatal morbidity and mortality due to the possibility of 
meconium aspiration syndrome. The associations found could be explained by less efficient 
placentation and increased myometrial stiffness in the presence of suboptimal maternal 
thyroid function. 
Future perspectives 
The induction rates are thought to rise even further in the coming decade, as the 
unwillingness of both patients and clinicians to wait for spontaneous labour, with the risk of 
stillbirth, decreases. Especially since more recent studies have found that the odds for CS are 
not increased with an induction of labor we expect to see rising induction rates, which will 
then become more comparable to international figures. Currently, many trials are running, 
e.g. to induction for postdates and to preterm induction for hypertension and preeclampsia. 
We expect that those results will lead to a further increase of induction rates. 
Historically, the CS rates in the Netherlands were and still are low compared to other 
Western countries. However, we foresee a trend of CS that will continue to rise. Deliveries in 
the Netherlands become more medicalized, women are generally older, have a higher BMI 
and there are more women with a previous CS. Those women are all ‘at-risk’ for a CS. 
Maternal thyroid function during pregnancy is a topic of ongoing interest. Currently there is 
much controversy about the need for universal screening, although the benefit of 
levothyroxine treatment and the cost-effectiveness of universal screening have already been 
proven29,35,36. This thesis can further contribute to the discussion, as besides the known 
effects of thyroid dysfunction on certain obstetric outcomes, such as preterm birth, it shows 
that suboptimal maternal thyroid function is associated with other major obstetric 
outcomes, such as CS rates, IUGR and MSAF. Basic future research should focus on 
determining whether there is a TSH-receptor on myometrial tissue. We advocate universal 
screening at the beginning of pregnancy, instead of individual case-finding based on non-
specific symptoms, to offer pregnant women optimal care for themselves and their 
offspring. Diagnosis and treatment of suboptimal thyroid function might  not only be 
important for optimal major obstetric outcomes, but also for the prevention and / or early 
recognition and treatment of maternal postpartum thyroid dysfunction. The possible benefit 
of rigorously monitoring maternal thyroid function during pregnancy on  
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Chapter 1 provides a general introduction of this thesis. Firstly, concerns about perinatal 
mortality in the Netherlands are discussed, after which trends in induction and Caesarean 
sections (CS) rates in the past decade are described. There is an increased trend in number 
of inductions, as well as in number of CS. The relation between inductions and the odds for 
CS are currently being debated. There are conflicting results about the perinatal and 
maternal outcome in relation to increased inductions and CS. In the second part of the 
introduction there is attention for the physiologic changes of the thyroid function during 
pregnancy and the known associations of suboptimal maternal thyroid function and 
obstetric outcome.  
The aim of this thesis was to analyze whether increased induction and CS-rates in the 
Netherlands have led to better perinatal and maternal outcomes and whether suboptimal 
maternal thyroid function is of influence on those obstetric outcomes. 
Chapter 2 describes the trends of induction and Caesarean section rates in relation to 
obstetric outcomes. It is a retrospective nationwide cohort study over a period of ten years 
with data from the Dutch perinatal registry. Women who delivered between 2000 and 2009 
after 24 weeks gestation were included in the study and classified using the Ten Group 
Classification system. We found that the overall Caesarean section rate increased from 
13.0% in 2000 to 15.4% in 2009. In 2000 the largest contributors to the CS-rate were groups 
1, 2 and 6 (nulliparous women at term, single cephalic fetus in spontaneous labor and 
induced and nulliparous breeches at term). In 2009 there has been a shift. The largest 
contributors to the absolute number of CS were groups 1, 2 and 5 (previous CS). 
Furthermore, an increase in induction of labor and prelabor CS was seen in the period from 
2000 to 2009. For the nulliparous women (groups 1 and 2) this trend was statistically 
significant (P<0.001), but for the multiparous women (groups 3 and 4) this was not the case 
(p=0.78). As the induction and CS-rates did not show similar trends we concluded that 
induction was not directly associated with CS in out cohort. 
For groups 1-4 the stillbirths were analyzed. A decreasing trend was shown, with a decrease 
of more than 100% within the ten-year period. The largest decrease was seen in groups 2 
and 4. Overall perinatal mortality was also steadily going down. Contrary, maternal 
postpartum hemorrhage was found to increase gradually over the years (P<0.001). The 
highest rates of postpartum hemorrhage were seen in the intervention groups of prelabor 
CS and inductions. Perinatal morbidity, defined as an Apgar-score below 7 after 5 minutes, 
has slightly decreased over the ten-year period. Most low Apgar-scores are found in 
nulliparous women where an induction of labor or prelabor CS is performed (group 2).   
Chapter 3 describes the association between maternal thyroid function and operative 
vaginal delivery rates and CS rates in a prospective cohort of women in spontaneous labor at 
term. Furthermore, the reasons for operative deliveries were determined. 872 women were 
included for data-analysis. In 19.9% (n=125) of those women a ventouse of forceps delivery 
was performed or a CS. Women who underwent an operative vaginal delivery (OVD) or CS 
had a significantly higher TSH and lower fT4 at 12 weeks gestation (TSH 1.63 mIU/L versus 
1.46 mIU/L and fT4 12.9 pmol/L versus 13.4 pmol/L respectively). Women who underwent 
an OVD or CS for failure to progress in second stage of labor (delayed expulsion) had higher 
mean TSH levels (p=0.026) and lower mean fT4 levels (p=0.030) in all trimesters, adjusted for 
BMI, maternal age, parity and gestational age when compared to women with a 
spontaneous delivery or an OVD or CS for different reasons.  
Chapter 4 provides a literature review on the topic of meconium stained amniotic fluid 
(MSAF). Some authors have found an association between fetal distress and MSAF whilst 
other have not. The latter suggest that MSAF should be seen as a physiologic sign of fetal 
ripening. Some authors claim that a distinction should be made between primary MSAF, 
which is present at the time of membrane rupture, and new-onset or secondary MSAF. 
Primary MSAF is associated with fetal ripening and thus physiology, whilst secondary MSAF 
is a sign of fetal distress. Furthermore, there have been some reports which have shown an 
independent association between MSAF and peripartum infections.  
In conclusion we suggest that MSAF should be seen as a symptom, rather than a syndrome 
and that it should be interpreted against other factors, such as the fetal heart rate pattern or 
the presence of maternal fever. 
Chapter 5 is a prospective cohort study, which analyses the association between maternal 
thyroid function and the presence of MSAF. 1051 women with a term delivery (≥37 weeks) 
were included for analysis. When assessing all births, there was no difference found in 
thyroid function for women with or without MSAF. However, it is known that the most 
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important risk factor for the presence of MSAF is the term of gestation. In our cohort the 
likelihood of MSAF increased by 63% for every week of gestation from 37 weeks onwards. 
When the ‘at-risk’ population for MSAF was analyzed in more detail, we found that high 
normal TSH at 36 weeks gestation was an independent risk factor for the presence of MSAF 
in pregnancies ≥41 weeks gestation (n=157) with an O.R. of 1.61, corrected for multiple 
confounders such as fetal distress, the duration of the first stage of labor and maternal age. 
Another independent risk factor for the presence of MSAF ≥41 weeks gestation was 
nulliparity, with an O.R. of 2.0. Maternal fT4 was not associated with an increased risk of 
MSAF.  
Chapter 6 describes the relation between maternal thyroid function and small for 
gestational age neonates (SGA). SGA was defined as the lowest 10th percentile of population 
based birth weight percentiles, corrected for parity, gestational age and sex of the baby. We 
included only deliveries that were at term (≥37 weeks), with a total number of 1051 
deliveries. Of those, there were 70 (6.7%) SGA neonates. We defined high TSH at each 
trimester using the group as its own reference, with an upper reference limit of > 97.5th 
percentile. These cut-offs were 3.28 mIU/L, 3.0 mIU/L and 3.29 mIU/L, at 12, 24 and 36 
weeks, respectively. SGA neonates were significantly more often born to the women with a 
high TSH. With multiple logistic regression analysis with SGA as dependent variable and high 
TSH at any trimester as independent variable, adjusting for multiple confounders, we found 
that the occurrence of smoking, pre-eclampsia and high TSH were independent risk factors 
for SGA neonates. High TSH at any trimester had an O.R. of 3.3 (95% C.I. 1.39-7.53) for the 
birth of SGA neonates. Low TSH (≤2.5th percentile) and FT4 were not associated with the 
incidence of SGA neonates. 
Chapter 7 consists of a general discussion of this thesis. Conclusions to the main research 









In hoofdstuk 1 wordt een inleiding van dit proefschrift gegeven. Als eerste wordt er 
aandacht besteed aan zorgen rondom de perinatale sterfte in Nederland en vervolgens 
worden de trends van keizersneden en inleidingen in de afgelopen tien jaar besproken.  Er 
wordt een toenemende trend gezien in het aantal inleidingen en in het aantal (geplande) 
keizersneden. Momenteel is er een discussie gaande over de mogelijke relatie tussen het 
inleiden van de baring en een verhoogd risico op  het krijgen van een keizersnede. Daarnaast 
zijn er in de literatuur tegenstrijdige resultaten beschreven over het verhoogde aantal 
inleidingen en keizersneden en het effect hiervan op perinatale en maternale uitkomsten. In 
het tweede deel van de introductie is aandacht voor de fysiologische veranderingen van de 
schildklier tijdens de zwangerschap en de bekende associaties tussen suboptimale maternale 
schildklierfunctie en obstetrische uitkomsten.  
Het doel van dit proefschrift was enerzijds om te analyseren of meer inleidingen en 
keizersneden hebben geleid tot betere perinatale en maternale uitkomsten, en anderzijds 
om te onderzoeken of suboptimale maternale schildklierfunctie van invloed is op 
obstetrische uitkomsten. 
In hoofdstuk 2 wordt de inductie- en keizersnedetrend in Nederland beschreven en de 
effecten hiervan op obstetrische uitkomsten. Het is een landelijke, retrospectieve 
cohortstudie over een periode van 10 jaar, met data van Perinatale Registratie Nederland 
(PRN). Alle vrouwen die tussen 2000 en 2009 bevielen na een zwangerschapsduur van 24 
weken werden geïncludeerd. Zij werden ingedeeld volgens het tien-groepen classificatie 
systeem, ook wel “Robson-systeem”.  Het algemene keizersnedepercentage is in de 
studieperiode gestegen van 13.0% in 2000 tot 15.4% in 2009. In 2000 hadden de vrouwen in 
groep 1, 2 en 6 het grootste aandeel in het totaal aantal keizersneden (nulliparae à-terme 
met een eenling in hoofdligging, spontaan in partu of na inductie en nulliparae met een 
eenling in stuitligging). In 2009 heeft er een verschuiving plaatsgevonden en hadden groepen 
1, 2 en 5 (eerdere keizersnede) het grootste aandeel in het totaal aantal keizersneden. Ook 
was er een verschuiving te zien naar een groter aantal vrouwen die ingeleid werden of een 
primaire sectio Caesarea kregen. Voor de nulliparae was deze trend statistisch significant 
(P<0.001). Voor de multiparae echter niet (p=0.078). De trendlijnen voor inleidingen en 
keizersneden over de studieperiode waren dusdanig verschillend dat wij concludeerden dat 
in ons cohort inleidingen geen direct effect hadden op het aantal uitgevoerde keizersneden.  
In de studieperiode werd het aantal vrouwen met een antenatale sterfte in groep 1 t/m 4 
bestudeerd (intra-uteriene vruchtdood, IUVD). Een dalende trend werd gezien voor het 
aantal IUVD’s, met een daling van meer dan 100% over de 10 jaar. De grootste daling vond 
plaats in groepen 2 en 4. De totale perinatale sterfte is ook gedaald. Hier staat tegenover dat 
het aantal vrouwen met een fluxus postpartum (>1000mL bloedverlies) gestaag toenam over 
de jaren (p<0.001). De grootste aantallen fluxus werden gevonden in die groepen waar een 
obstetrische interventie (een inleiding of keizersnede) plaatsvond. Naast perinatale sterfte is 
ook het aantal kinderen met een lage apgar-score afgenomen gedurende de jaren. De 
meeste kinderen met een apgar-score onder de zeven na vijf minuten worden gevonden in 
groep 2, de nulliparae met een inleiding of geplande keizersnede.  
Hoofdstuk 3 is een prospectieve cohortstudie naar vrouwen die spontaan in partu zijn, 
waarbij de associatie tussen suboptimale maternale schildklierfunctie en een hoger aantal 
kunstverlossingen wordt bestudeerd. Vervolgens werden de verschillende redenen voor een 
kunstverlossing nadere geanalyseerd. 872 vrouwen werden geïncludeerd, waarvan in 125 
gevallen (19.9%) een vaginale kunstverlossing of keizersnede werd uitgevoerd. Vrouwen 
waarbij een kunstverlossing werd uitgevoerd hadden een significant hoger TSH (1.63mIU/L 
versus  1.46mIU/L) en significant lager fT4 (12.9 pmol/L versus 13.4 pmol/L) bij 12 weken 
zwangerschap. Vrouwen die een kunstverlossing ondergingen voor niet vorderen van de 
uitdrijving hadden een significant hoger TSH gedurende de hele zwangerschap (P=0.026) en 
een significant lager fT4 gedurende de hele zwangerschap (P=0.030), gecorrigeerd voor BMI, 
leeftijd, zwangerschapduur en pariteit, vergeleken met vrouwen met een spontane bevalling 
of een kunstverlossing voor een andere reden.  
Hoofdstuk 4 is een overzicht van de literatuur over meconiumhoudend vruchtwater. 
Sommige studies laten een associatie zien tussen foetale nood en meconiumhoudend 
vruchtwater, terwijl andere studies dit niet aantonen. In die laatste studies wordt 
gesuggereerd dat meconiumlozing een fysiologisch mechanisme is door uitrijping van de 
foetus. Verder maken sommige auteurs onderscheid tussen primaire en secundaire 
meconiumlozing. Bij de eerste vorm is er al sprake van meconiumhoudend vruchtwater bij 
het breken van de vliezen, terwijl bij de tweede vorm er een verschuiving optreedt van 
helder naar meconiumhoudend vruchtwater. Primaire meconium zou samenhangen met 
fysiologische rijping van de foetus, terwijl secundaire meconium een teken is van foetale 
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nood. Daarnaast zijn er een aantal studies die een onafhankelijke relatie beschrijven tussen 
meconiumhoudend vruchtwater en peripartum infecties. Wij concluderen dan ook dat 
meconiumhoudend vruchtwater gezien moet worden als een symptoom, in plaats van als 
een syndroom, en dat het in het licht moet worden gezien van andere factoren, zoals het 
CTG.  
Hoofdstuk 5 is een prospectieve studie die de associatie tussen maternale schildklierfunctie 
en meconiumhoudend vruchtwater bestudeerd bij à-terme zwangerschappen. 1051 
vrouwen werden geïncludeerd voor deze studie. Voor de totale groep vrouwen werd geen 
verschil gevonden in schildklierwaardes bij vrouwen met helder of meconiumhoudend 
vruchtwater. Het is echter bekend dat de meeste belangrijke determinant voor het hebben 
van meconiumhoudend vruchtwater de zwangerschapsduur is. In ons cohort nam de kans op 
meconiumhoudend vruchtwater met 63% toe voor elke extra week zwangerschapsduur 
vanaf 37 weken. Bij een subgroepanalyse van de ‘at-risk’ vrouwen met een 
zwangerschapsduur ≥41 weken (n=157), vonden wij een onafhankelijke, statistisch 
significante relatie, tussen meconiumhoudend vruchtwater en een hoog normaal TSH bij 36 
weken zwangerschap (O.R. 1.61). Bij deze regressie-analyse werd gecorrigeerd voor 
meerdere factoren, zoals de duur van de ontsluiting, foetale nood en maternale leeftijd. Ook 
nullipariteit bleek een onafhankelijke risicofactor bij zwangerschappen ≥41 weken voor 
meconiumhoudend vruchtwater, met een O.R. van 2.0. Maternaal fT4 was niet geassocieerd 
met het voorkomen van meconiumhoudend vruchtwater.  
Hoofdstuk 6 is een studie naar de relatie tussen maternale schildklierfunctie en het 
voorkomen van foetale groeibeperking (small for gestational age, SGA). SGA werd 
gedefinieerd als een geboortegewicht onder de 10e percentiel, gecorrigeerd voor de 
zwangerschapsduur, pariteit en het geslacht van de baby. De curves die gebruikt werden zijn 
curves op populatieniveau van de PRN. In totaal werden 1051 à-terme vrouwen 
geïncludeerd. 70 kinderen voldeden aan de definitie van SGA (6.7%). Hoog TSH werd 
gedefinieerd als een TSH ≥97.5 percentiel ten opzichte van de rest van de 
onderzoekspopulatie op enig moment in de zwangerschap. De afkapwaardes die op deze 
manier werden gedefinieerd zijn 3.28 mIU/L, 3.0 mIU/L en 3.29mIU/L bij een 
zwangerschapsduur van respectievelijk 12, 24 en 36 weken. SGA kinderen werden significant 
vaker geboren bij moeders met een hoog TSH. Bij multivariate logistische regressie analyse 
bleek dat roken, pre-eclamspie en hoog TSH onafhankelijke risicofactoren waren in ons 
cohort, voor het krijgen van een SGA kind. Hoog TSH had een O.R. van 3.3 (95% BI 1.39-7.53) 
voor het krijgen van een SGA neonaat. Laag TSH en fT4 waren niet geassocieerd met het 
krijgen van groeibeperkte kinderen. 
Hoofdstuk 7 is een algemene discussie van dit proefschrift. Hierin worden de 
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Dankwoord 
“Men moet niet nadenken over het eindresultaat van zijn werk, zoals men ook niet reist om 
aan te komen, maar om te reizen” – von Goethe. 
Toch ben ik maar al te blij dat het eindresultaat nu voor ons ligt. Er zijn velen mensen die ik 
voor de prettige reis ernaar toe wil bedanken. Zonder het aanstekelijke enthousiasme van 
velen en de steun en mogelijkheden die ik heb gekregen zou de reis vele malen hobbeliger 
geweest zijn.  
Professor Pop. Wat startte met een vaag idee tijdens een uurtje brainstormen is in een 
stroomversnelling geraakt. Door u kreeg ik de mogelijkheid om in te stromen in dit 
onderzoek. Ik waardeer uw intensieve begeleiding ontzettend. De revisies van de artikelen 
kwamen altijd de volgende dag alweer binnen in mijn inbox. Daarnaast mocht ik ook te allen 
tijden bellen en hebben we de nodige uurtjes doorgebracht in Riethoven achter SPSS. Uw 
enthousiasme heeft er in grote mate voor gezorgd dat dit proefschrift afgerond is. 
Professor Oei. Dank dat u ondanks uw drukke agenda de tijd heeft gevonden om mee te 
werken aan dit proefschrift en op te treden als mijn promotor. 
Dr. Kuppens, beste Simone. Wat ben ik trots dat jij mijn co-promotor bent. Jouw 
enthousiasme en motivatie zijn zeer inspirerend. Mede dankzij jou is dit project binnen 
afzienbare tijd afgerond. Telefoontjes ’s avonds en in het weekend met hypotheses of 
nieuwe artikelen waren niet zeldzaam. Ongelofelijk hoe goed jij je literatuur bij kan houden 
en hoe ontzettend veel parate kennis je hebt. Ik wil je ontzettend bedanken voor de kansen 
die je me geboden hebt. Zowel klinisch als opleider, als binnen dit onderzoek. We zijn zeker 
nog niet klaar met ons onderzoekstraject en ik hoop dat we nog vele inspirerende 
momenten mogen beleven.  
De leden van de promotiecommissie: Prof. Dr. Franx, Prof. Dr. Stagnaro-Green, Dr. 
Mercelina-Roumans en Dr. Robson wil ik danken voor de tijd en energie om mijn proefschrift 
te lezen en kritisch te beoordelen. Dank dat ik mijn proefschrift ten overstaan van u mag 
verdedigen. Thank you for the time and energy to carefully read and comment on my 
manuscript and thank you that you came to the Netherlands for the opposition. 
Dr. Hasaart. Wat een eer dat u wil plaatsnemen in mijn corona. Ik ben u heel dankbaar voor 
uw altijd kritische commentaar, zowel tijdens het schrijven van dit proefschrift als tijdens 
mijn werk als ANIOS. Ik heb veel gehad aan uw no-nonsense adviezen en ik wil u bedanken 
dat ik mede dankzij u de tijd en ruimte heb gekregen om me te ontplooien in het Catharina 
Ziekenhuis. 
Dr. Wijnen, beste Hennie. Hartelijk dank dat ik gebruik mocht maken van de zeer uitgebreide 
dataset die je hebt aangelegd voor je eigen onderzoek. Hierdoor was het mogelijk onze 
hypotheses te toetsen en een aantal van de artikelen in dit proefschrift te kunnen schrijven. 
Mede-auteurs: H Oosterbaan, E Hutton en H Vader, dank voor jullie medewerking aan het 




Stichting Perinatale Registratie. Dank dat ik gebruik mocht maken van de dataset. Daarnaast 
bedankt voor jullie gastvrijheid als ik in Utrecht was voor de data-analyses en jullie 
begeleiding hierbij.  
Maatschap gynaecologie Catharina Ziekenhuis. Wat een fijne en leerzame tijd heb ik als 
ANIOS gehad in het Catharina Ziekenhuis! Bij jullie is mijn liefde voor het vak begonnen. 
Dankzij jullie vertrouwen is het gelukt om dit proefschrift af te ronden naast mijn baan. De 
betrokkenheid vanuit de gehele maatschap was enorm.  
(Oud)-assistenten Catharina Ziekenhuis. Dank voor de leerzame tips, maar vooral voor het 
‘spuien’ en de gezellige momenten. Fijn dat er in het rooster rekeningen werd gehouden met 
mijn wetenschapsdagen. 
Verloskundigen, verpleegkundigen, poli-medewerkers en secretaresses van het Catharina 
Ziekenhuis. Wat een bijzondere, inspirerende mensen zijn jullie. Altijd persoonlijk 
geïnteresseerd en altijd bereid om het voor mij zo gemakkelijk mogelijk te maken. Dank voor 
de fijne samenwerking! 
De maatschap gynaecologie Zuyderland MC Heerlen wil ik bedanken voor de interesse in 
mijn onderzoek en voor alle leerzame momenten die ik sinds de start van mijn opleiding tot 
gynaecoloog heb mogen meemaken. 
Assistenten Zuyderland MC Heerlen. Jullie zijn een superteam! Hardwerkende meiden die als 
1 team voor elkaar klaar staan. Dank voor de fijne tijd tot nu toe en ik kijk uit naar de periode 
die nog gaat komen. 
Verloskundigen, verpleegkundigen, kraamverzorgsters, poli-medewerkers en secretaresses 
van het Zuyderland MC Heerlen. Dank voor de fijne werksfeer die jullie met elkaar creëren 
en bedankt voor de gastvrije ontvangst. 
Lieve Evie, lieve Loes, paranimfen. Ik vind het heel bijzonder dat jullie op deze dag achter mij 
staan. Vanaf de middelbare school al vriendinnen, en hoewel we elkaar nu minder zien dan 
we eigenlijk alle drie zouden willen; toch is het altijd weer meteen goed als we samen zijn. Ik 
ben trots dat we deze periode alle drie wat te vieren hebben. Loes, jij gaat je opleiding 
afronden en hiermee de langverwachte volgende stap in je carrière zetten. Evie, binnenkort 
sta ik achter jou zoals je nu bij mij staat. Je gaat promoveren op een prachtig onderzoek.   
Lieve Ida. Samen onze “WESP-stage” doorlopen bij de gynaecologie. Hier hebben we elkaar 
vanachter de Excel-sheets snel goed leren kennen. Naast collega inmiddels geworden tot 
vriendin. Ik vind het super dat je verder gaat met mijn onderzoek in het Catharina Ziekenhuis 
en dat ik je heb mogen inwerken als ANIOS. Die opleidingsplek komt er ook voor jou! 
Lieve Annelies en lieve Dionne, ‘club Stuurloos’. Met z´n drietjes hebben we al een hoop 
mooie dingen beleefd en al een hoop dingen kunnen afstrepen op onze bucketlist! Na de 
afronding van dit proefschrift komt er iets meer tijd om af te spreken en nog meer 
hoogtepunten te gaan beleven. Bedankt dat jullie begrijpen dat ik soms ´van de radar´ ben 
als ik dienst heb of als ik een deadline had voor mijn proefschrift.  
Hockeyteam HC Eindhoven. Met jullie op het veld staan was en is een heerlijke uitlaatklep. 
Op het veld zijn we bloedfanatiek, maar daarnaast is er gelukkig genoeg tijd over voor een 
hoop gezelligheid! 
Jolanda, Sandra en Lina. Lieve schoonfamilie, dank voor jullie interesse in mijn werk. De deur 
staat bij jullie altijd open en dat wordt zeer gewaardeerd. 
Lieve opa en oma. Wat ben ik blij dat jullie op deze dag aanwezig kunnen zijn. Ik vind het 
heel bijzonder dat jullie trots op de eerste rij zullen zitten tijdens mijn verdediging.  
Lieve pap en mam. Dankzij jullie heb ik de mogelijkheden gekregen om te gaan studeren en 
om me te ontwikkelen tot arts. Ik vind het ongelofelijk hoe geïnteresseerd jullie zijn in mij en 
in mijn werk. Jullie kennen mijn dienstrooster beter dan ik! Daarnaast leren jullie me als 
rasechte levensgenieters om alle mooie momenten van het leven te koesteren. Ik ben blij 
dat jullie er vandaag bij zijn. 
Lieve, lieve Rick. Jouw geduld en begrip zijn eindeloos. Zonder jou was het me niet gelukt om 
dit proefschrift af te ronden. Je weet niet half hoeveel jouw steun mij helpt. Vanaf nu komt 





Loes Monen werd op 02-03-1989 geboren te Eindhoven als enig kind. Zij doorliep zowel de 
basis- als de middelbare school in Eindhoven. In 2000 startte zij met de opleiding 
geneeskunde aan Maastricht University. In 2010 volgde zij een keuzecoschap gynaecologie 
en obstetrie in het Academisch Ziekenhuis Paramaribo te Suriname. Haar wetenschappelijke 
stage werd doorlopen bij de gynaecologie in het Orbis Medisch Centrum Sittard. Haar semi-
arts stage werd in het Catharina ziekenhuis Eindhoven gevolgd, ook binnen de gynaecologie 
en obstetrie. Hier kon zij na haar afstuderen in 2012 direct aan de slag als arts niet in 
opleiding tot specialist (opleider Dr. S. Kuppens, plaatsvervangend opleider Dr. T. Hasaart). 
Hier werd ook het begin gemaakt van het promotie-onderzoek. In januari 2015 is zij gestart 
met de opleiding tot gynaecoloog binnen het cluster Maastricht in het Atrium Medisch 
Centrum te Heerlen (opleider Dr. P. Mercelina, plaatsvervangend opleider Dr. N. Smeets).  
Loes woont samen in Eindhoven met Rick van de Bunt. 
 
